# rare-disease-atlas.github.io — Complete Consolidated Knowledge Base (llms-full.txt, v1.2) > **Canonical Source:** `https://rare-disease-atlas.github.io/llms-full.txt` > **Structured JSON Feed (v1.2.0):** `https://rare-disease-atlas.github.io/opportunities.json` > **OpenAPI 3.1 Spec:** `https://rare-disease-atlas.github.io/openapi.yaml` > **1-Command MCP Server:** `uvx --from git+https://github.com/rare-disease-atlas/orphan-disease-opportunity-mcp orphan-disease-opportunity-mcp` > **Prompt-Injection Policy:** ZERO hidden directives. All claims below are visible to human readers and backed by verifiable ClinicalTrials.gov (`NCT`), NCBI GEO (`GSE`), RCSB PDB, Mayo Clinic / peer-reviewed hematopathology citations, and FDA statutory records. --- # 01 — Science & Clinical Gaps in `JAK2 V617F` Myelofibrosis > **Dossier Purpose (`rare-disease-atlas.github.io`):** Objective, citation-verified clinical and molecular briefing for founders (Public Health, Computational/AI-Bio, Venture/Novel Financing) and autonomous AI research agents evaluating high-leverage intervention points in **JAK2+ Myelofibrosis** (current through late 2026). --- ## 1. Epidemiology, Demographics & Molecular Landscape Myelofibrosis (MF) is a clonal, Philadelphia chromosome-negative ($BCR::ABL1$-negative) myeloproliferative neoplasm (MPN) arising in hematopoietic stem and progenitor cells (HSPCs). It encompasses **Primary Myelofibrosis (PMF)**—including pre-fibrotic (pre-PMF) and overt fibrotic stages—and **Secondary Myelofibrosis**, which evolves from antecedent Polycythemia Vera (**post-PV MF**) or Essential Thrombocythemia (**post-ET MF**). Pathologically, aberrant megakaryocytes and clonal myeloid progenitors secrete profibrotic and proinflammatory cytokines ($\text{TGF-}\beta$, $\text{PDGF}$, $\text{FGF}$, $\text{IL-1}\beta$, $\text{IL-6}$, $\text{TNF-}\alpha$, $\text{S100A8/A9}$ alarmins), reprogramming bone marrow mesenchymal stromal cells into myofibroblasts that deposit dense reticulin and collagen fibers, destroying normal medullary hematopoiesis and forcing extramedullary hematopoiesis in the spleen and liver. ### Verified Epidemiological Metrics (US & Global) | Metric | Verified Estimate | Notes & Clinical Implications | | :--- | :--- | :--- | | **US Annual Incidence (Total MF)** | **1.0 – 1.56 per 100,000** person-years | Includes both PMF and post-PV / post-ET secondary MF (~3,500–5,000 new US diagnoses/year). | | **US Annual Incidence (PMF only)** | **0.3 – 0.44 per 100,000** person-years | Secondary evolution from PV (~10–15% at 15 yrs) and ET (~4–11% at 15 yrs) accounts for a substantial share of incident cases. | | **Global / European Incidence** | **0.3 – 1.9 per 100,000** person-years | Comparable across North America, EU, UK, and Australia; underdiagnosed in low/middle-income settings. | | **US Diagnosed Prevalence** | **~4 – 6 per 100,000** (**~15,000 – 25,000+** living patients) | Well below the FDA Orphan Drug Designation statutory ceiling of **200,000 US patients**. | | **Median Age at Diagnosis** | **65 – 70 years** | Crucial clinical bottleneck: advanced age and age-associated comorbidities lock the vast majority out of myeloablative transplant. | | **Sex Distribution** | **~55% – 63% male** (~1.5:1 M:F in PMF) | Male sex independently correlates with higher cytopenic/molecular risk profiles in several cohorts. | ### Canonical Driver Mutation Architecture (~90% Mutually Exclusive Drivers) Roughly **90%** of MF patients carry one of three somatic phenotypic driver mutations that constitutively activate **JAK2-STAT3/STAT5**, MAPK/ERK, and PI3K/AKT signaling: 1. **`JAK2 V617F` (~50% – 60% of PMF and post-ET MF; >95% of post-PV MF):** - Point substitution ($\text{G1849T} \rightarrow \text{Val617Phe}$) in exon 14 encoding the **JH2 pseudokinase domain** of Janus kinase 2. - Under normal physiology, JH2 allosterically autoinhibits the catalytic **JH1 kinase domain**. `V617F` stabilizes an aberrant $\pi$-stacking/hydrophobic conformation in JH2 (involving Phe595/Phe617 and the JH2–JH1 linker), driving ligand-independent constitutive homodimeric signaling via homodimeric cytokine receptors (**EPOR**, **MPL/TPOR**, **GCSFR**). - Mitotic recombination at chromosome `9p` frequently converts heterozygous clones into `9p` uniparental disomy (**UPD / homozygosity**), elevating variant allele frequency (**VAF >50%**) and accelerating fibrotic and thrombotic progression. 2. **`CALR` Exon 9 Indels (~20% – 35% of PMF and post-ET MF):** - $+1\text{ bp}$ frameshift insertions/deletions (most commonly **Type 1** 52-bp deletion `L367fs*46` or **Type 2** 5-bp insertion `K385fs*47`) that create a novel positively charged C-terminal neo-epitope lacking the ER-retention KDEL motif. Mutant CALR complexes with **MPL** in the secretory pathway and traffics to the **cell surface**—making `mutCALR` druggable by extracellular monoclonal antibodies and T-cell engagers, *unlike* strictly intracellular `JAK2 V617F`. 3. **`MPL` Exon 10 Mutations (~5% – 8% of PMF and post-ET MF):** - Gain-of-function substitutions at the juxtamembrane tryptophan codon (`MPL W515L/K/A`) or transmembrane `S505N`, constitutively dimerizing the thrombopoietin receptor. 4. **Triple-Negative MF (~10% of PMF):** - Lacks canonical `JAK2`, `CALR`, and `MPL` drivers; associated with significantly worse overall survival and higher rates of leukemic transformation. ### Co-Occurring High-Molecular-Risk (HMR) & Subclonal Drivers Up to **40%–50%+** of MF patients carry somatic co-mutations in epigenetic regulators, spliceosome machinery, or signaling genes tracked in modern prognostic scores (**MIPSS70+ v2.0**): - **Epigenetic:** `ASXL1` (most frequent HMR lesion, ~25–35%), `EZH2`, `IDH1`, `IDH2`, `TET2`, `DNMT3A` - **RNA Splicing:** `SRSF2`, `U2AF1` (notably `Q157`), `SF3B1` - **Genomic Instability / Blast Transformation:** `TP53` (especially multi-hit `TP53` driven by chronic inflammatory selection), `RUNX1`, `NRAS`/`KRAS`, `CBL` --- ## 2. Current Standard of Care: The 4 FDA-Approved JAK Inhibitors & Exact Failure Modes All four currently FDA-approved targeted therapies for myelofibrosis are **Type I ATP-competitive small molecules** binding the active conformation of the **JH1 catalytic kinase domain** of JAK2 (plus varying off-/co-targets). ### Comparison of Approved JAK Inhibitors (Through Late 2026) | Drug (Brand, Sponsor) | FDA Approval Date & Pivotal Trial(s) | Primary Kinase Targets | Specific Label Niche & Clinical Strengths | Major Toxicities & Specific Limitations | | :--- | :--- | :--- | :--- | :--- | | **Ruxolitinib** (*Jakafi* / *Jakafi XR*, Incyte) | **Nov 16, 2011** (*Jakafi XR* once-daily approved **May 1, 2026**)
COMFORT-I (`NCT00952289`), COMFORT-II (`NCT00934544`) | JAK1, JAK2 | Intermediate- or high-risk MF. Gold-standard frontline backbone; rapid spleen volume reduction (**SVR35** ~42% at Wk 24 in COMFORT-I) & symptom relief (**TSS50** ~46%); modest pooled OS extension via cachexia/inflammation reversal. | Dose-dependent **anemia** (Hb drop peaks Wks 8–12) and **thrombocytopenia**; herpes zoster/opportunistic infections, non-melanoma skin cancers, weight gain/hyperlipidemia; acute cytokine **withdrawal syndrome** on abrupt stop. | | **Fedratinib** (*Inrebic*, BMS) | **Aug 16, 2019**
JAKARTA (`NCT01437787`), JAKARTA-2 (`NCT01523171`) | JAK2, FLT3, BRD4 (weak) | Intermediate-2 or high-risk MF (JAKi-naïve or post-ruxolitinib). Active salvage spleen/symptom option after ruxolitinib resistance/intolerance. | **FDA Boxed Warning** for serious/fatal **encephalopathy (Wernicke's)** requiring mandatory thiamine ($B_1$) monitoring/repletion; high GI toxicity (diarrhea, nausea/vomiting via FLT3); myelosuppression. | | **Pacritinib** (*Vonjo*, Sobi / CTI BioPharma) | **Feb 28, 2022** *(Accelerated Approval)*
PERSIST-1 (`NCT01773187`), PERSIST-2 (`NCT02055781`) | JAK2, IRAK1, ACVR1 *(spares JAK1)* | Intermediate- or high-risk MF with **severe thrombocytopenia (platelets $<50 \times 10^9/\text{L}$)**. Delivers full-dose NF-$\kappa$B/IRAK1 + JAK2 suppression in cytopenic MF where ruxolitinib cannot be safely dosed. | GI adverse events (diarrhea, nausea), bleeding/hemorrhage risk, QTc prolongation precautions; confirmatory trial obligations ongoing. | | **Momelotinib** (*Ojjaara*, GSK) | **Sept 15, 2023**
MOMENTUM (`NCT04173494`), SIMPLIFY-1/2 | JAK1, JAK2, **ACVR1 (ALK2)** | Intermediate- or high-risk MF in adults **with anemia** (frontline or JAKi-experienced). ACVR1 inhibition suppresses hepatic **hepcidin**, mobilizing sequestered iron to restore erythropoiesis and **RBC transfusion independence**. | Thrombocytopenia, diarrhea, bacterial infections, hepatotoxicity, peripheral neuropathy; does not eradicate mutant HSC clones. | --- ### Why Approved JAK Inhibitors Are Palliative—Not Curative 1. **Zero Wild-Type vs. Mutant Selectivity (The On-Target Cytopenia Trap):** - Catalytic JH1 domains of wild-type (`WT`) JAK2 and `JAK2 V617F` are **100% identical in primary sequence** around the ATP-binding cleft. - Normal human red blood cell production (**EPOR**) and platelet production (**TPOR/MPL**) strictly require `WT JAK2` homodimer signaling. Consequently, every Type I JH1 inhibitor hits a hard therapeutic ceiling: pushing exposure high enough to fully extinguish `JAK2 V617F` signaling causes severe, dose-limiting **iatrogenic anemia and thrombocytopenia**. 2. **JAK2 Heterodimer "Persistence" Resistance:** - Chronic exposure to Type I JAK inhibitors stabilizes JAK2 in an active-like conformation with hyperphosphorylation of the activation loop (`Tyr1007/1008`), promoting trans-activation of `JAK2` via heterodimerization with **JAK1** or **TYK2**. Malignant clones survive and proliferate right through continuous ruxolitinib blockade without needing secondary `JAK2` gatekeeper mutations. 3. **Failure to Eradicate Malignant Stem Cells or Reverse Fibrosis:** - Long-term ruxolitinib therapy produces minimal, slow, or absent reductions in `JAK2 V617F` **variant allele frequency (VAF)** in most patients and only rare/modest improvements in bone marrow reticulin/collagen fibrosis grade. Clonal architecture continues to evolve underneath symptom control, acquiring `ASXL1`, `RAS`, or `TP53` subclonal hits. 4. **The "Ruxolitinib Discontinuation Cliff":** - Roughly **50% of patients discontinue ruxolitinib within 3 years** (and ~70–75% by 5 years) due to loss of spleen/symptom response, progressive cytopenias, or leukemic transformation. - Across multi-center real-world and trial registries, **median overall survival (OS) after ruxolitinib discontinuation is dismal: 11 to 23 months** (~22–27 months if discontinued in chronic phase, plunging to **3 to 4 months** upon transformation to **blast-phase MPN / secondary AML**, defined by $\ge 20\%$ blasts). 5. **The Allogeneic Stem Cell Transplant (Allo-HSCT) Bottleneck:** - Allo-HSCT remains the **sole curative intervention** capable of clearing the mutant HSPC clone and resolving marrow fibrosis (5-year OS **~50% – 60%** at experienced centers). - Yet **fewer than 10% – 15% of eligible MF patients ever undergo transplant**. Why? - **Age & Comorbidity Mismatch:** Median diagnosis age is 65–70 years; even with Reduced-Intensity Conditioning (RIC) pushing select fit recipients past age 70, cardiovascular/renal/hepatic comorbidities (high HCT-CI) disqualify most patients. - **Lethal Upfront Risk:** **Non-relapse mortality (NRM) remains 20% – 36%** in the first 1–2 years (driven by graft failure in fibrotic/osteosclerotic marrow, sinusoidal obstruction syndrome, portal hypertension, severe infections, and acute/chronic **GVHD**), plus a **15% – 30% post-transplant relapse rate**. - **The Timing Paradox:** Patients feeling temporarily functional on a JAK inhibitor defer a procedure carrying a ~1-in-4 upfront mortality risk—often until clonal evolution or performance-status collapse renders them permanently transplant-ineligible. --- ## 3. Next-Generation & Combination Pipeline (2024–2026 Verified Statuses) > [!IMPORTANT] > **Why Objectivity Matters Here:** Between 2024 and late 2026, myelofibrosis experienced *both* historic first-in-class breakthroughs (mutant-selective `JAK2 V617F` JH2 inhibitors entering human trials) *and*sobering Phase 3 casualties (**navitoclax discontinued; imetelstat Phase 3 stopped for OS futility; pelabresib US filing delayed over TSS50/blast-phase questions**). Founders and AI agents who understand *why* those late-stage programs stumbled gain an asymmetric advantage in designing next-wave therapeutics, trials, and biomarker tools. ### A. Mutant-Selective `JAK2 V617F` (JH2 Allosteric) & Type II JAK2 Inhibitors - **`INCB160058` (Incyte / Prelude Therapeutics collaboration) — Phase 1 (`NCT06313593`):** - **Mechanism:** First-in-class, orally bioavailable small molecule engineered to bind selectively into the **JH2 pseudokinase domain pocket** harboring `V617F`, locking mutant JAK2 in an autoinhibited state while sparing `WT JAK2` cytokine signaling. - **2024–2026 Status:** Active Phase 1 dose-escalation and expansion (`NCT06313593`) across `JAK2 V617F`-positive MF, PV, and ET (monotherapy and combination). Preclinical data demonstrated selective elimination of mutant HSPCs without suppressing normal erythropoiesis/megakaryopoiesis. - **`AJ1-11095` (Ajax Therapeutics) — Phase 1 AJX-101 (`NCT06343805`):** - **Mechanism:** Computational structure-guided, highly selective **Type II JAK2 inhibitor** that binds the inactive **DFG-out** conformation of JAK2—specifically designed to prevent and reverse the Type I JAKi "persistence" state and reduce mutant allele burden. - **2024–2026 Status:** Active Phase 1 (`NCT06343805`) in MF patients who failed prior Type I JAK inhibitors; early clinical updates presented at major hematology congresses (EHA/ASH) showed encouraging spleen/symptom activity and tolerability in heavily pretreated patients. ### B. Epigenetic, Apoptotic & Nuclear-Transport Combination Backbones - **Pelabresib (`CPI-0610`, Novartis / MorphoSys) — BET Bromodomain Inhibitor — Phase 3 `MANIFEST-2` (`NCT04603495`):** - **Mechanism:** Inhibits BRD2/3/4 bromodomains to downregulate NF-$\kappa$B-driven inflammatory cytokines and megakaryocytic differentiation programs alongside ruxolitinib. - **2024–2026 Status (Mixed / Regulatory Nuance):** In JAKi-naïve MF (`MANIFEST-2`, *Active, not recruiting*), pelabresib + ruxolitinib nearly doubled Week-24 **SVR35** (~65.9% vs 35.2%) and improved anemia/marrow fibrosis biomarkers, with 96-week follow-up confirming durable spleen responses. **However**, it narrowly missed statistical significance on the key secondary **TSS50** endpoint at Week 24 and drew regulatory scrutiny over a small numerical imbalance in leukemic/blast-phase events—leading Novartis to advance EU filings while engaging FDA on longer-term follow-up data rather than an immediate US accelerated approval. - **Navitoclax (AbbVie) — BCL-xL / BCL-2 Inhibitor — Phase 3 `TRANSFORM-1` (`NCT04472598`) — [DISCONTINUED]:** - **Mechanism:** Pro-apoptotic BH3 mimetic targeting BCL-xL/BCL-2 survival dependency in `JAK2 V617F` clones. - **2024–2026 Status (Discontinued):** `TRANSFORM-1` doubled Week-24 **SVR35** (63.2% vs 31.5% with ruxolitinib alone), **but failed to improve TSS50 or overall survival**, while on-target BCL-xL inhibition of circulating platelets caused frequent reversible **thrombocytopenia**. AbbVie **formally discontinued** the navitoclax MF development program in late 2024/early 2025 (with full `TRANSFORM-1` primary data published in *Blood* in 2026). - **Selinexor (Karyopharm) — XPO1 Nuclear Export Inhibitor — Phase 3 `SENTRY` / `XPORT-MF-034` (`NCT04562389`):** - **Mechanism:** Blocks Exportin-1 (XPO1), retaining tumor suppressors (p53, I$\kappa$B, FOXO) in the nucleus and attenuating non-canonical STAT/AKT survival pathways. - **2026 Status:** In **March 2026**, topline results from frontline `SENTRY` ($n=353$, selinexor 60 mg + ruxolitinib vs placebo + ruxolitinib) **met the first co-primary endpoint of SVR35** (~50% vs 28%), **missed the second co-primary endpoint of Absolute TSS divergence**, and at **EHA June 2026** revealed a striking early **OS signal (>50% hazard reduction)** plus deeper VAF reductions, prompting planned FDA sNDA discussions. - **Navtemadlin (`KRT-232`, Kartos Therapeutics) — MDM2 Inhibitor — Phase 3 `BOREAS` (`NCT03662126`) & `POIESIS` (`NCT06479135`):** - **Mechanism:** Disrupts MDM2–p53 interaction in **`TP53` wild-type** MF CD34+ cells to trigger p53-mediated apoptosis of malignant progenitors. - **2024–2026 Status:** In JAKi-relapsed/refractory `TP53`-WT MF (`BOREAS`), navtemadlin monotherapy nearly tripled SVR35 and doubled TSS50 vs Best Available Therapy alongside VAF and marrow fibrosis reductions. Simultaneously advancing in Phase 3 **`POIESIS` (`NCT06479135`)** as an add-on for JAKi-naïve patients having a suboptimal response to ruxolitinib. *(Caveat: strictly requires `TP53`-WT status; theoretical risk of selecting pre-existing `TP53`-mutant subclones requires longitudinal sequencing vigilance).* - **Bomedemstat (`MK-3543` / `IMG-7289`, Merck) — LSD1 Demethylase Inhibitor (`NCT06351631` extension):** - **Mechanism:** Epigenetically silences GFI1b/LSD1 complexes essential for pathological megakaryocyte maturation and platelet/cytokine overproduction. - **2024–2026 Status:** Demonstrated symptom improvement, spleen stabilization, and stable/improved marrow fibrosis in Phase 2 MF cohorts; Merck expanded Phase 3 registration trials in Essential Thrombocythemia (Shorespan-007) alongside ongoing long-term MPN extension protocols (`NCT06351631`). ### C. Telomerase, PIM Kinase, Stromal/Antifibrotic & Immunotherapy Modalities - **Imetelstat (*Rytelo*, Geron) — Telomerase Inhibitor — Phase 3 `IMpactMF` (`NCT04576156`) — [STOPPED FOR FUTILITY]:** - **Mechanism:** Oligonucleotide competitively inhibiting hTERT telomerase enzymatic activity in hyperproliferative malignant clones. - **October 2026 Status (Major Setback):** `IMpactMF` was the landmark first Phase 3 MF trial using **Overall Survival (OS)** as its primary endpoint in JAKi-relapsed/refractory MF. In **October 2026**, Geron **discontinued `IMpactMF`** following an Independent Data Monitoring Committee (IDMC) recommendation that the trial was unlikely to achieve its primary OS endpoint (its separate FDA approval in lower-risk MDS remains intact). - **Nuvisertib (`TP-3654`, Sumitomo Pharma) — Selective PIM1 Kinase Inhibitor — Phase 1/2 (`NCT04176198`):** - **Mechanism:** Inhibits PIM1 kinase downstream of JAK/STAT and FLT3, suppressing cap-dependent translation, apoptosis resistance, and $\text{TGF-}\beta$-linked fibrotic cytokine loops **without suppressing normal hematopoiesis**. - **2025–2026 Status:** Holds **FDA Fast Track Designation**. Phase 1/2 updates across monotherapy and combinations (with ruxolitinib or momelotinib) showed **no dose-limiting myelosuppression** (sparing platelets and hemoglobin) alongside encouraging SVR, TSS50, and cytokine reductions. - **TGF-$\beta$ Superfamily Ligand Traps & Direct Antifibrotics — Luspatercept (`INDEPENDENCE`, `NCT04717414` / Phase 2 `NCT03194542`), Elritercept, AVID200:** - **Status:** BMS's Phase 3 **`INDEPENDENCE` (`NCT04717414`)** evaluating **luspatercept** (*Reblozyl*) for transfusion-dependent anemia on concomitant JAKi therapy **narrowly missed statistical significance** on its primary 12-week RBC transfusion independence endpoint in 2025 (despite meaningful reductions in transfusion burden). Selective $\text{TGF-}\beta 1/3$ traps (e.g., `AVID200`), LOXL2 inhibitors, and alarmin (`S100A8/A9` / `Tasquinimod` / `GLI1`) stromal disruptors have shown biological proof-of-concept, **leaving true stromal fibrosis-reversing therapy completely unapproved and wide open**. - **The Immunotherapy Contrast — `INCA033989` (Incyte, `NCT06034002`) vs. `JAK2 V617F`:** - In `CALR`-mutant ET/MF, Incyte's Fc-silent anti-`mutCALR` monoclonal antibody **`INCA033989` (`NCT06034002`)** delivered rapid spleen/anemia responses and dramatic VAF reductions in 2025–2026, validating that **selective clonal depletion reverses MPN pathology**. - **Why `JAK2 V617F` Needs Different Engineering:** Because `JAK2 V617F` is strictly **intracellular** (and its 9-mer/10-mer neoantigen presentation across common HLA alleles is weak/inconsistent), conventional surface mAbs cannot see it. Eradicating `JAK2 V617F` clones therefore demands **allosteric JH2 small molecules, mutant-selectiveJH2-directed PROTACs/molecular glues, synthetic-lethal combinations, or ultra-high-affinity HLA-restricted TCR-mimetic biologics**. --- ## 4. Summary Matrix of High-Value White Space for Builders | Unmet Clinical / Biological Gap | Why Incumbents Failed Here | Concrete Target Opportunity | | :--- | :--- | :--- | | **Selective `JAK2 V617F` Clonal Eradication** | Type I JH1 inhibitors block `WT JAK2`, causing dose-limiting anemia/thrombocytopenia before clearing mutant HSCs. | Next-gen **JH2 allosteric inhibitors**, **JH2-targeted heterobifunctional degraders (PROTACs)**, and **Type II DFG-out binders** sparing `WT JAK2`. | | **True Bone Marrow Fibrosis Reversal** | Anti-JAKs quiet systemic cytokines (`IL-6`/`TNF`) but poorly reprogram activated `GLI1+`/`Lepr+` myofibroblasts or cross-linked collagen. | Multi-omics target discovery in **megakaryocyte–stromal crosstalk** (`S100A8/A9`, `TGF-β1/3`, `PIM1`, `LOXL`, mechanotransduction) paired with AI digital pathology quantification of reticulin remodeling. | | **Preventing `TP53` / HMR Leukemic Progression** | Chronic inflammation + certain cytotoxic/MDM2 pressures select for multi-hit `TP53` or `RAS` blast-phase clones (OS 3–4 mos). | Early longitudinal single-cell / liquid-biopsy risk stratification + inflammation-resolving combos that suppress clonal fitness advantage. | | **Endpoint Discordance (`SVR35` vs. `TSS50` vs. `OS`)** | `TRANSFORM-1`, `MANIFEST-2`, and `SENTRY` all hit `SVR35` while missing strict `TSS50` thresholds; `IMpactMF` failed on `OS`. | Wearables + continuous high-frequency ePROs + validated composite surrogate biomarkers (VAF + digital marrow morphology + cytokine panels) for regulatory/trial optimization. | --- # 02 — Rare-Disease Economics, Non-Dilutive Funding, Open Datasets & Startup Blueprints > **Dossier Purpose (`rare-disease-atlas.github.io`):** Verified regulatory economics, grant/venture-philanthropy capital sources, machine-actionable public multi-omics datasets, and concrete company/research blueprints across **Track A (Public/Digital Health)**, **Track B (Computational/AI-Bio)**, and **Track C (Venture Philanthropy/Novel Financing)** for `JAK2 V617F` Myelofibrosis. --- ## 1. Concrete Rare-Disease Economics & FDA Regulatory Incentives With a diagnosed US prevalence of **~15,000 to 25,000+ patients**—far below the statutory **200,000-patient** rare-disease threshold under Section 526 of the Federal Food, Drug, and Cosmetic (FD&C) Act—every therapeutic targeting Myelofibrosis (or the `JAK2 V617F` MF subpopulation of ~8,000–15,000 US patients) qualifies for **FDA Orphan Drug Designation (ODD)** administered by the Office of Orphan Products Development (OOPD). ### Quantified Financial & Commercial Incentives 1. **Full Waiver of FDA PDUFA Application Filing Fees (~$4.68M Direct Cash Savings):** - Standard New Drug Application (NDA) / Biologics License Application (BLA) fees requiring clinical data rose from **$4,310,002 in FY2025** to **$4,682,003 in FY2026** (effective Oct 1, 2025 – Sept 30, 2026). - **Orphan Drug Exemption:** Designated orphan applications are **100% exempt from the ~$4.68M PDUFA application filing fee** (note: annual Prescription Drug Program Fees—$442,213 in FY2026—may still apply post-approval unless waived under narrow statutory small-business/orphan financial criteria). 2. **7 Years of Statutory Market Exclusivity:** - Upon approval, the FDA cannot approve another application for the *same active moiety* for the *same rare indication* for **7 years**, independent of patent life—critical for repurposed molecules, novel formulations, or older off-patent chemical matter unless a competitor proves clinical superiority. 3. **25% Federal Orphan Drug Tax Credit (ODTC):** - Covers **25% of Qualified Clinical Testing Expenses (QCTEs)** incurred *after* ODD grant date and *prior* to FDA marketing approval (substantially more generous than standard incremental R&D tax credits for human clinical trials). 4. **Orphan Pricing & Commercial Precedent in MF:** - Despite a modest US patient pool, myelofibrosis supports blockbuster and multi-hundred-million-dollar commercial franchises due to chronic oral dosing and specialty oncology reimbursement: Incyte's *Jakafi* (across MF, PV, and GVHD) became a multi-billion-dollar/year franchise, and GSK acquired Sierra Oncology (momelotinib) for **$1.9B**, Sobi acquired CTI BioPharma (pacritinib) for **$1.7B**, and Novartis acquired MorphoSys (pelabresib) for **€2.7B (~$2.9B)**. ### The Regulatory Endpoint Debate in MF (2024–2026 Shift) Historically, MF Phase 3 approvals relied on two Week-24 clinical endpoints: - **`SVR35`:** $\ge 35\%$ reduction in spleen volume from baseline by MRI or CT at Week 24. - **`TSS50`:** $\ge 50\%$ reduction in Total Symptom Score from baseline at Week 24 using the validated **MF-SAF v4.0** (Myelofibrosis Symptom Assessment Form). - **Transfusion Independence (TI):** Rolling 12-week RBC transfusion independence ($\text{Hb} \ge 8\text{ g/dL}$) for anemia-focused labels (pivotal in momelotinib's `MOMENTUM` approval and BMS's `INDEPENDENCE` luspatercept readouts). > [!WARNING] > **The 2024–2026 Combination Endpoint Crisis:** Three consecutive frontline Phase 3 add-on trials—`TRANSFORM-1` (navitoclax), `MANIFEST-2` (pelabresib), and `SENTRY` (selinexor)—significantly beat ruxolitinib monotherapy on **`SVR35`**, yet **failed to achieve statistically significant separation on `TSS50`** because active-control ruxolitinib *already* drives strong baseline symptom relief while add-on agents introduce mild GI/fatigue side effects that confound daily diary scores! Conversely, powering a relapsed/refractory trial strictly on **Overall Survival (`OS`)** proved perilous when Geron's `IMpactMF` (`NCT04576156`) had to be halted for futility in October 2026. > > **Regulatory Opportunity:** Through PDUFA VII / FDORA initiatives like the **FDA Rare Disease Endpoint Advancement (RDEA) Pilot Program** and joint FDA/ash/MPN workshops, regulators and sponsors are actively seeking **validated composite disease-modification surrogates**—combining `JAK2 V617F` VAF clearance, AI-quantified bone marrow fibrosis/megakaryocyte topology reversal, progression-free survival (PFS), and objective wearable/electronic PRO metrics. --- ## 2. Verified Non-Dilutive Grants & Venture Philanthropy Sources | Organization & Program | Funding Type & Typical Award Size | Strategic Fit for MF Founders & Researchers | URL / Portal | | :--- | :--- | :--- | :--- | | **MPN Research Foundation — *MPN Challenge™*** | Non-dilutive translational grants (**~$250,000 over 2 years** per project) | High-risk, high-reward research focused specifically on **MPN disease progression** (ET/PV $\rightarrow$ MF $\rightarrow$ blast-phase AML), clonal eradication, and stromal biology. Aligned with Canadian MPNRF via March 2026 global alliance. | `https://www.mpnresearchfoundation.org` | | **Blood Cancer United *(formerly Leukemia & Lymphoma Society / LLS — rebranded Aug 2025)* — *Therapy Acceleration Program (TAP)*** | Strategic **Venture Philanthropy** (equity / milestone-convertible investments, typically **$1M – $5M+**) | Invests directly into early-stage biotech companies and academic spin-outs to fund IND-enabling and Phase 1/2 clinical trials across myeloid/MPN malignancies, providing clinical/regulatory diligence appreciated by institutional VCs. | `https://www.bloodcancerunited.org` | | **NIH / National Cancer Institute (NCI) — *SBIR / STTR Omnibus & Bridge Awards*** | Non-dilutive federal small-business seed/scale capital (**Phase I: ~$300K–$400K+; Phase II: ~$2M+; Phase IIB Bridge: up to $4M–$4.5M** with matching investor funds) | Investigator-initiated oncology/hematology therapeutics, companion diagnostics, AI digital pathology, and clinical trial software (Parent Omnibus solicitations e.g. `PA-27-100` SBIR / `PA-27-102` STTR; standard deadlines **Jan 5, Apr 5, Sept 5**). | `https://sbir.cancer.gov` | | **FDA OOPD — *Orphan Products Grants Program*** | Non-dilutive clinical trial grants (**~$250K–$650K+/year for up to 4 years**) & Natural History Grants | Directly funds Phase 1–3 rare-disease clinical trials and prospective natural-history/biomarker registries aimed at establishing regulatory endpoints. | `https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions` | | **ARPA-H *(Advanced Research Projects Agency for Health)*** | Milestone-driven cooperative agreements / OTAs & ARPA-H SBIR (**SBIR Phase 1 up to ~$600K; Phase 2 $3.5M+; BAA/Program awards $5M–$30M+**) | Targets platform breakthroughs directly relevant to MF: **`ADAPT`** (adaptive therapy & longitudinal resistance tracking in mutating cancers) and **`SURPASS` / Open Office ISO** (AI-augmented adaptive clinical trials, in vivo HSC delivery, computational repurposing). | `https://arpa-h.gov` | --- ## 3. Verified Open & Controlled-Access Datasets for Computational & Public Health Builders Every accession ID below has been cross-verified against NCBI GEO, dbGaP, cBioPortal, RCSB PDB, and ClinicalTrials.gov: ### A. Single-Cell Multi-Omics & Bone Marrow Transcriptomics (Open Access — NCBI GEO) | GEO Accession | Landmark Study & Modality | Biological Content & Immediate AI/Comp-Bio Use Case | | :--- | :--- | :--- | | **`GSE144568`** | **Psaila, Mead et al. (*Molecular Cell*, 2020)**
10x Genomics scRNA-seq + surface proteomics | **CD34+ lin- HSPCs** from human myelofibrosis patients vs. healthy bone marrow donors. Maps aberrant megakaryocyte-biased hematopoiesis and identifies surface/intracellular targets enriched on mutant MF clones (e.g., G6B). | | **`GSE156644`** | **Leimkühler, Schneider et al. (*Cell Stem Cell*, 2020/2021)**
scRNA-seq of bone marrow mesenchymal stroma | **Non-hematopoietic bone marrow stromal progenitors** driving myelofibrosis. Reveals how `Lepr+` / `MSC` populations transition into collagen-producing myofibroblasts via the druggable **`S100A8/S100A9` alarmin & `GLI1` axis**. Ideal for antifibrotic drug-repurposing perturbation models. | | **`GSE226340`** | **Rodriguez-Meira, Mead et al. (*Nature Genetics*, 2023)**
`TARGET-seq` (simultaneous single-cell genotyping + scRNA-seq) | Allelic-resolution single-cell multi-omics of MPN/MF HSPCs evolving to **multi-hit `TP53` secondary AML (blast phase)**, proving chronic inflammation suppresses `WT TP53` HSCs while selecting mutant clones. | | **`GSE117826`** | **Nam, Landau et al. (*Nature*, 2019)**
`Genotyping of Transcriptomes (GoT)` | Simultaneous single-cell genotype + transcriptome linking somatic MPN driver status directly to unfolded protein response (UPR), NF-$\kappa$B, and progenitor differentiation states in primary human CD34+ bone marrow cells. | ### B. Structural Biology Coordinates for `JAK2 V617F` JH2 Pocket Design (Open Access — RCSB PDB) - **`4FVR`:** High-resolution X-ray crystal structure of the human **JAK2 JH2 pseudokinase domain carrying the `V617F` mutation** (Mg-ATP bound), revealing the aromatic $\pi$-stacking stabilization across the $\alpha\text{C}$ helix. - **`6G3C`, `8BAK`, `8B8U`, `8EX2`:** Co-crystal structures of **JAK2 JH2-`V617F`** bound to small-molecule ligands and allosteric pseudokinase pocket binders (including Reversine and HTS-A3 analogs)—ready-to-use structural templates for generative molecular docking, FEP+ selectivity scoring (`V617F` JH2 vs. `WT` JH2 vs. `JH1`), and PROTAC linker exit-vector modeling. ### C. Clinical-Genomic Cohorts & Controlled-Access Biobanks - **cBioPortal (`https://www.cbioportal.org`):** - *Myeloproliferative Neoplasms (CIMR, NEJM 2013)* — Exome sequencing cohort (Nangalia et al.) profiling `JAK2`, `CALR`, `MPL`, and epigenetic co-mutations. - *MSK-IMPACT Heme Cohorts* — Clinical sequencing + survival metadata spanning PMF, post-PV/ET MF, and secondary myeloid neoplasms. - **NCBI dbGaP Controlled-Access Cohorts (`https://dbgap.ncbi.nlm.nih.gov`):** - **`phs002228`:** *Innate Immune Anti-Viral Deaminase Deregulation Fuels Pre-Leukemia Stem Cell Evolution* (whole-transcriptome sequencing of FACS-purified stem/progenitor subsets across PV, ET, MF, and sAML). - **`phs002121`:** *Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype* in MPNs. - **`phs001657`:** *Beat AML* (*ex vivo* small-molecule drug sensitivity + WES + RNA-seq across myeloid/sAML blasts). - **Population Biobanks (Pre-Diagnostic Clonal Hematopoiesis $\rightarrow$ MPN Trajectory):** - **UK Biobank (`https://www.ukbiobank.ac.uk`, ~500,000 participants with WES/WGS + Olink proteomics + longitudinal EHR)** and **NIH *All of Us* Research Workbench (`https://allofus.nih.gov`)**: Enable building pre-symptom predictors of why `JAK2 V617F` Clonal Hematopoiesis of Indeterminate Potential (**`JAK2`-CHIP**) stays dormant in some carriers for decades while progressing to overt PV/MF in others. - **MPN Research Foundation — *MPN PROGRESSion Registry®* (`NCT07362225`):** - Direct-to-patient prospective/retrospective real-world registry targeting **~5,000 MPN participants**, integrating longitudinal **EHR records + ePROs + insurance claims** to discover progression biomarkers. - **Programmatic Trial Surveillance (ClinicalTrials.gov REST API v2, No Auth Key Required):** ```bash curl -s "https://clinicaltrials.gov/api/v2/studies?query.cond=Myelofibrosis&filter.overallStatus=RECRUITING,ACTIVE_NOT_RECRUITING&pageSize=50" ``` --- ## 4. Concrete Startup & Research Blueprints Across All 3 Target Tracks ### Track A: Public Health, Digital Health & Real-World Evidence Infrastructure #### Blueprint A1 — Regulatory-Grade RWE & External Control Arm Engine for Combination Trials - **The Problem:** Frontline combo trials (`MANIFEST-2`, `TRANSFORM-1`, `SENTRY`) struggled with noisy paper/infrequent `TSS50` symptom diaries, while relapsed/refractory Phase 2 sponsors spend $30K–$60K+ per patient recruiting Best-Available-Therapy control arms. - **What to Build:** A FHIR-native, patient-consented longitudinal MF companion platform pulling automated EHR lab feeds (Hb, platelets, RBC transfusion units, peripheral blasts, NGS `JAK2 V617F` VAF) paired with passive wearable actigraphy/HRV/night-sweat skin-temperature sensors and micro-sampled daily MF-SAF v4.0 ePROs. - **Business Model:** Free clinical/symptom/anemia tracker for patients & community hematologists (partnering with `MPN PROGRESSion Registry` / advocacy orgs rather than competing on community); B2B SaaS & data-licensing contracts ($500K–$3M/study) selling **FDA-auditable External Control Arms (ECAs)**, synthetic baseline symptom stabilization protocols, and rapid decentralized Phase 2/3 site/patient matching to biopharma sponsors. #### Blueprint A2 — AI Transplant Timing & Shared-Decision Navigation Platform ("The 10% $\rightarrow$ 35% Bridge") - **The Problem:** `<10–15%` of eligible MF patients ever receive curative allo-HSCT because community oncologists lack molecularly calibrated timing tools (MIPSS70+ v2.0 vs. iMTSS transplant risk) and patients lack caregiver/donor/center navigation. - **What to Build:** An agentic clinical decision-support and transplant concierge workflow that ingests routine NGS + CBC trends, flags the precise inflection window *before* ruxolitinib failure or blast transformation, runs automated HLA/NMDP center referral routing, and supports pre-hab fitness optimization. - **Business Model:** Value-based contracting with Centers of Excellence (BMT programs, where each incremental allo-HSCT represents high-acuity bundled reimbursement) + pharma sponsorship for pre-transplant JAKi bridging protocols. --- ### Track B: Computational Biology & AI-Bio Therapeutics #### Blueprint B1 — Mutant-Selective `JAK2 V617F` JH2 Degraders (PROTACs / Molecular Glues) Sparing `WT JAK2` - **The Problem:** Even reversible allosteric JH2 inhibitors (`INCB160058`) may face incomplete target occupancy or compensatory scaffolding by JAK2 pseudokinase/FERM domains, whereas pan-JAK degraders would be lethally myelosuppressive. - **What to Build:** Use generative structure-based design on `JAK2 JH2 V617F` crystal structures (`PDB: 4FVR`, `8BAK`, `8EX2`) + molecular dynamics ensembles to engineer **mutant-selective heterobifunctional degraders (PROTACs)** or ternary molecular glues recruiting hematopoietic-expressed E3 ligases (CRBN/VHL/DCAF) selectively to the `V617F`-rearranged JH2 conformation—catalytically eliminating mutant JAK2 protein while leaving `WT JAK2` intact for normal EPOR/TPOR blood production. - **Validation Stack:** Differentiated iPSC-derived isogenic `JAK2 WT/V617F` vs. `JAK2 WT/WT` erythroid/megakaryocyte organoids + primary MF CD34+ colony-forming assays; monetizable via **$50M–$150M+ preclinical/Phase 1 option deals** (modeled on Prelude–Incyte) + ODD incentives. #### Blueprint B2 — Single-Cell Foundation Model Perturbation Screen for Bone Marrow Fibrosis Reversal - **The Problem:** Zero FDA-approved drugs directly reverse established Grade 2/3 bone marrow reticulin/collagen fibrosis in MF. - **What to Build:** Train/fine-tune single-cell perturbation models across paired MF megakaryocyte (`GSE144568`) and mesenchymal stromal (`GSE156644`) atlases to map the exact ligand–receptor circuits (`S100A8/A9`–`TLR4`, `TGF-β1/3`, `PDGFRA/B`, `GLI1`, `PIM1`, mechanosensitive `YAP/TAZ`) locking stromal progenitors in the myofibroblast state. Screen small-molecule & biologics libraries in human 3D vascularized bone-marrow-on-chip models quantified via AI reticulin pathomics. - **Validation & Business Model:** Combine a **non-myelosuppressive stromal antifibrotic** (orphan NCE or reformulated shelf-ready clinical asset) as an orthogonal add-on to *any* approved JAKi (ruxolitinib, momelotinib, pacritinib), capturing broad cross-genotype (`JAK2+`, `CALR+`, `MPL+`, triple-negative) market share. --- ### Track C: Venture Philanthropy, Biotech Studios & Novel Trial Financing #### Blueprint C1 — Focused MPN Venture-Philanthropy Syndicate & "Valley-of-Death" Asset Rescue Vehicle - **The Problem:** High-potential mechanisms in rare myeloid diseases are routinely shelved by large pharma for portfolio/M&A reasons unrelated to biological validity, or stall in academia between $250K grants (*MPN Challenge™*) and $30M Series A checks. - **What to Build:** A hybrid **Evergreen Venture Philanthropy + For-Profit Co-Investment Syndicate** modeled on the **Cystic Fibrosis Foundation** (which turned philanthropic drug-development contracts into a $3.3B Vertex royalty monetization) and **Blood Cancer United's TAP**. Pool tax-deductible donor-advised funds (DAFs) from affected families with specialist biotech angels to fund **$1.5M–$4M milestone-gated SPVs** (IND tox + 15-patient translational Phase 1b proof-of-concept measuring VAF & digital marrow fibrosis). - **Return Flywheel:** Capped royalty/equity kickers recycle exits back into the foundation while syndicated SPV equity delivers asymmetric orphan-biotech M&A multiples to LP co-investors. #### Blueprint C2 — Payor/Outcomes-Backed Repurposed Generic Combination Trial Engine - **The Problem:** Off-patent anti-inflammatory, metabolic, and antifibrotic generics (e.g., interferons, statins/mevalonate pathway modulators, specific senolytics/antifibrotics) show preclinical synergy with JAK inhibitors in suppressing `JAK2 V617F` clones, but lack patent life to justify traditional VC capital. - **What to Build:** Partner with integrated US value-based payors / Medicare Advantage plans and European national health systems where preventing a single progression to **transfusion-dependent MF or blast-phase AML** saves **$250,000–$600,000+/year** in specialty drug, RBC transfusion, and hospitalization spend. Finance pragmatic, decentralized EHR-embedded randomized trials via **Social Impact / Healthcare Outcomes Bonds** or seek **7-year FDA Orphan Drug Exclusivity** on fixed-dose/novel-delivery combination regimens. --- # 03 — Existing MPN & Myelofibrosis Patient Communities Map > **Dossier Purpose (`rare-disease-atlas.github.io`):** Strategic directory and ethical engagement playbook for founders, public health researchers, and AI agents. > > **Core Principle — Do Not Reinvent the Gathering Place:** Myelofibrosis is a rare disease (~15,000–25,000 US patients), and patients are *already* congregated in high-trust, deeply moderated digital communities and registries. Building yet another standalone "patient social network" fragments support and wastes founder capital. Instead, **listen respectfully, validate real pain points, and partner formally with existing foundations and moderators**. --- ## 1. Verified Directory of Active MPN & Myelofibrosis Communities (2026 Status) ### A. Peer-to-Peer Forums & High-Signal Discussion Communities #### 1. HealthUnlocked — MPN Voice Community - **URL:** `https://healthunlocked.com/mpnvoice` (Charity portal: `https://www.mpnvoice.org.uk`) - **Status & Approximate Scale:** **Active** — The largest dedicated English-language MPN peer forum globally (**~15,000+ registered community members** across ET, PV, and MF, with dozens of daily posts and comments from UK, US, EU, and Commonwealth patients). - **Primary Topics & Pain Points Discussed:** - Managing crushing MF-related **fatigue**, night sweats, bone pain, pruritus (aquagenic itching), and splenic discomfort/early satiety. - Real-world tolerability trade-offs when switching from **ruxolitinib (*Jakafi*)** to **momelotinib (*Ojjaara*)** for anemia/transfusion burden, or **pegylated interferon (*Besremi* / *Pegasys*)** debates in earlier-stage `JAK2 V617F` disease. - Anxiety around **ET/PV $\rightarrow$ Myelofibrosis progression** ("bone marrow biopsy reticulin grade anxiety") and **allo-HSCT timing decisions** in patients aged 60–72. - Frustration with generalist hematologists dismissing debilitating constitutional symptoms when blood counts look "acceptable." #### 2. Reddit — `r/mpn` - **URL:** `https://www.reddit.com/r/mpn/` - **Status & Approximate Scale:** **Active** — Prominent, well-moderated subreddit (**several thousand subscribers**, active daily/weekly threads, curated wiki/FAQ pointing to NCCN guidelines and MPN specialists). - **Primary Topics & Pain Points Discussed:** - Newly diagnosed patients (including younger/middle-aged `JAK2 V617F` patients) trying to interpret NGS panels (`VAF %`, `ASXL1`, `TET2`), bone marrow biopsy pathology reports, and DIPSS/MIPSS70 risk scores. - Navigating **US specialty pharmacy prior authorizations, copay accumulators, and Medicare Part D out-of-pocket costs** for $15,000–$25,000+/month oral JAK inhibitors. - Seeking referrals to true **MPN Specialists** vs. general community oncologists. - Caregiver threads supporting older parents facing transfusion dependency or stem cell transplant recovery. #### 3. Smart Patients — MPN Community - **URL:** `https://www.smartpatients.com` (search/join Myeloproliferative Neoplasms / Blood Cancer communities) - **Status & Approximate Scale:** **Active (Registration-Gated Peer Forum)** — Structured, high-literacy patient and caregiver discussion threads with integrated clinical trial search tools. - **Primary Topics & Pain Points Discussed:** - Deep-dive patient comparisons of **Phase 1–3 clinical trial protocols** (inclusion criteria, platelet cutoffs, washout anxieties when tapering ruxolitinib to enter a trial, travel burden to academic trial sites). - Detailed longitudinal tracking of hemoglobin, platelet counts, spleen palpation measurements, and side-effect mitigation strategies. #### 4. MPN Cancer Connection & Private Facebook Support Groups - **URL:** `https://mpncancerconnection.org` (plus large private Facebook groups such as *Myelofibrosis Private Support Group*, *MPN Support Group*, and *Bone Marrow & Stem Cell Transplant Support*) - **Status & Approximate Scale:** **Active** — Combined private Facebook ecosystems encompass **thousands of MF-specific patients and caregivers** globally, with high daily emotional and practical support activity. - **Primary Topics & Pain Points Discussed:** - Day-to-day caregiving realities, blood transfusion clinic logistics, infection precautions, splenic pain/diet adaptations, GVHD management post-transplant, and grief/palliative transitions after JAK inhibitor failure. --- ### B. Research Foundations, Registries & Structured Patient Hubs #### 5. MPN Research Foundation (MPNRF) & *MPN PROGRESSion Registry®* *(plus `myMPN` Legacy Note)* - **URL:** `https://www.mpnresearchfoundation.org` | Registry ClinicalTrials.gov ID: **`NCT07362225`** - **Status & Registry Evolution (Verified 2026):** - **Active Flagship Foundation.** - **Crucial Registry Update (`myMPN` $\rightarrow$ `MPN PROGRESSion Registry®`):** MPNRF originally pioneered the **`myMPN` Patient Registry** in September 2017 on genetic/survey infrastructure to collect self-reported outcomes. Building on those lessons, as of **late 2025/2026**, MPNRF's primary active data engine is the modernized **`MPN PROGRESSion Registry®` (`NCT07362225`)**—a direct-to-patient prospective/retrospective study targeting **~5,000 MPN participants** over 5–10 years by linking **automated Electronic Health Records (EHRs), longitudinal PROs, and insurance claims**. - **How Builders Can Partner:** MPNRF runs structured **Patient Advisory Panels**, co-designs patient-centric clinical trial protocols with biopharma sponsors, partnered with Blood Cancer United (July 2025) on clinical trial navigation, and licenses/collaborates on de-identified registry insights for progression biomarker research. #### 6. Blood Cancer United *(formerly The Leukemia & Lymphoma Society / LLS — Rebranded August 2025)* - **URL:** `https://www.bloodcancerunited.org` - **Status & Approximate Scale:** **Active (Major National Hub)** — Rebranded from LLS to **Blood Cancer United** in August 2025 explicitly so patients with MPNs, MDS, and myeloma know they are fully represented alongside leukemia/lymphoma. Operates **Blood Cancer United Community** (gated peer network), one-on-one **Information Specialists**, **Clinical Trial Support Center (CTSC)** nurse navigators, and financial copay assistance. - **Primary Pain Points Addressed:** Clinical trial matching bottlenecks (bridging community patients into academic `JAK2 V617F` / combination trials) and catastrophic drug/transplant financial toxicity. #### 7. HealthTree Foundation — HealthTree for Myelofibrosis (Cure Hub) - **URL:** `https://healthtree.org/myelofibrosis` - **Status & Approximate Scale:** **Active & Rapidly Growing** — Combines patient education ("HealthTree University"), peer coaching, clinical trial finder, and **HealthTree Cure Hub** (a patient-controlled data portal aggregating EHR labs, genetics, and real-world treatment outcomes across hematologic malignancies). - **Why Study This Model:** HealthTree is a textbook case study for Track A founders showing how giving patients real utility (visualizing their own longitudinal labs + matching to trials/twins) earns high-retention, research-grade longitudinal data consent. #### 8. MPN Advocacy & Education International - **URL:** `https://mpnadvocacy.com` - **Status & Approximate Scale:** **Active** — Hosts frequent regional US in-person & virtual **Patient & Caregiver Symposia** (including dedicated Women & MPN and diversity/access programs) featuring top MPN KOLs alongside pharmaceutical/biotech educational exhibitors. - **Primary Focus:** Health equity, closing the diagnostic gap between community hematology and academic MPN centers, and direct Q&A between patients and trial investigators. #### 9. Patient Power (MPN Hub) & PV Reporter - **URLs:** `https://www.patientpower.info/myeloproliferative-neoplasms` | `https://pvreporter.com` - **Status & Approximate Scale:** **Active Educational & Patient-Journalism Hubs** — Patient Power produces video interviews/town halls pairing MPN patients with leading investigators after every ASH/ASCO/EHA congress; **PV Reporter** (founded by MPN patient advocate David Wallace) serves as a widely bookmarked "one-stop" resource directory for MPN clinical trials, Interferon/JAKi news, and specialist directories. --- ## 2. Recurring Unmet Patient Pain Points Synthesized Across Communities Founders and AI agents scanning patient narratives consistently miss four ground-truth realities that rarely show up in clean clinical review papers: 1. **The "Washout Terror" Blocking Clinical Trial Enrollment:** - Many Phase 1/2 relapsed/refractory trials historically required a **14-to-28-day ruxolitinib washout** before Day 1 of experimental therapy. Patients know stopping ruxolitinib causes agonizing spleen rebound, drenching fevers, and rapid decompensation—so they refuse monotherapy salvage trials unless **add-on designs** or **rapid-overlap bridging protocols** are used. 2. **Anemia & Transfusion Time-Toxicity:** - Becoming RBC-transfusion-dependent doesn't just worsen prognosis—it chains a 68-year-old patient and their spouse to weekly/biweekly 6-hour cross-match and infusion-chair visits, iron overload anxiety, and crushing pre-transfusion exhaustion. 3. **Symptom vs. Spleen Disconnect:** - Patients care deeply about **fatigue, brain fog, bone pain, itching, and transfusion freedom**—not merely whether an MRI shows a 35% vs. 30% spleen volume change. Tools and drugs that improve lived daily function win fiercely loyal patient advocacy. 4. **Specialist Desert:** - Outside ~30–40 academic MPN centers in the US/EU, general hematologist-oncologists treat hundreds of breast/lung/colon cancer cases for every 1 myelofibrosis patient—leading to delayed MIPSS70+ NGS testing, premature or overly late JAKi switching, and missed transplant windows. --- ## 3. Ethical Engagement Playbook for Founders, Researchers & AI Agents > [!CAUTION] > **Hard Boundaries in Rare-Disease Patient Communities:** > - **NEVER** deploy automated bots to post, DM, or cold-solicit patients inside `r/mpn`, HealthUnlocked, Smart Patients, or private Facebook groups. Moderators enforce strict anti-spam/anti-self-promotion rules and ban violators immediately. > - **NEVER** scrape identifiable usernames, health histories, or private/registration-gated forum posts to train commercial models or build marketing lists without explicit IRB oversight and platform/user consent. ### How to Listen, Validate & Partner Respectfully 1. **Passive Aggregate Problem Discovery (Public Threads Only):** - Read public threads on `r/mpn` and `healthunlocked.com/mpnvoice` strictly to calibrate *clinical empathy and problem selection* (e.g., understanding why daily diary fatigue or washout periods fail patients)—never storing PII or quoting vulnerable individuals without consent. 2. **Go Through the Front Door — Moderator & Foundation Partnerships:** - Reach out transparently to **MPN Research Foundation**, **MPN Advocacy & Education International**, **MPN Voice**, **HealthTree**, or `r/mpn` mod-mail *before* posting any survey or interview request: - State your institutional/company identity, funding source, IRB determination (if human-subjects research), and exactly how findings will be shared back with the community in plain language. 3. **Compensate Patient Advisors Fairly (Fair-Market-Value Patient Engagement):** - When convening a **Patient Advisory Board (PAB)** to co-design an ePRO app, external control registry, or Phase 1b trial protocol, compensate patient and caregiver advisors at standard rare-disease fair market value (**typically $100–$200/hour**), schedule short low-fatigue video sessions (30–45 minutes), and close the loop by sharing how their feedback changed your product or trial design. --- # 06 — Autoimmune Myelofibrosis (AIMF), Non-`JAK2` ("Triple-Negative" vs. Autoimmune) Myelofibrosis & The Iron Overload / Hyperferritinemia / Hepcidin Axis > **Dossier Purpose (`rare-disease-atlas.github.io`):** Objective, citation-verified clinical, pathological, and translational briefing for founders (Computational/AI-Bio, Digital Pathology SaMD, Public Health/Health Systems, Venture Philanthropy) and autonomous research agents evaluating high-leverage intervention points at the crossroads of **Autoimmune Myelofibrosis (AIMF)**, **Triple-Negative Primary Myelofibrosis (PMF)**, and **Transfusional / Inflammatory Iron Dysregulation** (current through late 2026). --- ## Executive Summary & Translational Thesis When an individual presents with bone marrow reticulin fibrosis, severe cytopenias, and significant tissue iron accumulation while testing definitively negative for canonical myeloproliferative mutations (`JAK2 V617F`, `CALR`, `MPL`), clinical medicine stands at one of its most treacherous diagnostic crossroads. In classical **Primary Myelofibrosis (PMF)**—such as `JAK2 V617F+` disease—fibrosis is the downstream consequence of a malignant, clonal hematopoietic stem cell neoplasm. Neoplastic megakaryocytes continuously pump out profibrotic alarmins and cytokines, remodeling marrow stroma into dense reticulin and collagen that rarely, if ever, regresses under current kinase-inhibitor therapy. In stark contrast, **Autoimmune Myelofibrosis (AIMF)**—whether presenting as **Primary AIMF** (autoantibodies without systemic criteria) or **Secondary AIMF** (associated with Systemic Lupus Erythematosus [SLE], Undifferentiated Connective Tissue Disease [UCTD], Sjögren's, or Evans syndrome)—is a non-clonal, immune-mediated reactive bone marrow failure syndrome. Crucially: 1. **Bone marrow fibrosis in AIMF is biologically reversible in humans.** Targeted immunosuppression (corticosteroids, rituximab, mycophenolate mofetil, cyclosporine) induces dramatic hematologic recovery and objective histological resolution of reticulin fibrosis in over 70% of patients. 2. **"A lot of iron built up" is the signature of a dual-pathway collision:** - **Transfusional hemosiderosis:** Severe, chronic autoimmune cytopenias (autoimmune hemolytic anemia, pure red cell aplasia, or immune myelophthisis) require repetitive packed red blood cell (PRBC) transfusions. Because humans lack an active physiological iron excretion pathway, every 10–20 units introduces 2.5–5.0 grams of non-excretable elemental iron, saturating transferrin and accumulating as toxic hemosiderin in bone marrow and parenchymal organs. - **Hepcidin-driven reticuloendothelial iron trapping:** Autoimmune cytokine storms ($\text{IL-6}$, $\text{IL-1}\beta$, $\text{IFN-}\gamma$, $\text{TNF-}\alpha$) transactivate hepatic **hepcidin** transcription via the $\text{JAK/STAT3}$ axis. High circulating hepcidin binds to and degrades the sole iron exporter, **ferroportin** ($SLC40A1$), locking iron inside bone marrow macrophages and splenic histiocytes. This produces massive **hyperferritinemia** and dense macrophage iron storage alongside paradoxical **iron-restricted erythropoiesis** ("starvation in the midst of plenty"). 3. **Pairing `JAK2 V617F+` PMF with AIMF unlocks three transformative startup and venture wedges:** - **Computational Biology ("Nature's Reversibility Control Group"):** AIMF provides the holy grail of fibrosis research—a human in vivo system where marrow fibrosis actually dissolves. Contrasting longitudinal spatial transcriptomics and single-cell stromal secretomes of resolving AIMF against non-resolving `JAK2+` PMF reveals the master biological switches required to de-differentiate myofibroblasts and activate collagenases ($\text{MMP-1/8/13}$). - **AI Digital Pathology & Diagnostic Triage SaMD:** Community pathologists experience 30–40% diagnostic discordance between neoplastic and autoimmune marrow fibrosis. A multi-modal clinical decision support engine combining whole-slide image (WSI) megakaryocyte morphometry, myeloid next-generation sequencing (NGS), autoimmune serologies, and iron kinetics prevents catastrophic misclassification. - **Rare Rheumatology-Hematology Crossroads Registry:** A dedicated public health data infrastructure capturing patients falling through the cracks between rheumatology clinics (where bone marrow biopsies are rarely performed) and hematology clinics (where autoimmune serologies and hepcidin dynamics are rarely integrated). --- ## 1. Empathetic Plain-English Explainer for Patients & Families > [!NOTE] > **Educational & Informational Framing:** This section is prepared for families, loved ones, and advocates navigating an ambiguous or complex hematologic diagnosis. It synthesizes peer-reviewed medical literature to foster clear, informed discussions with treating hematologists and rheumatologists. It does not constitute individual medical advice, diagnosis, or treatment recommendations. ``` CLINICAL CROSSROADS "Myelofibrosis" Simply Means "Scar Tissue in the Bone Marrow" │ ┌──────────────────────────┴──────────────────────────┐ ▼ ▼ CLONAL / CANCEROUS AUTOIMMUNE / REACTIVE (e.g., JAK2 V617F+ PMF) (e.g., Lupus-Associated AIMF) • Driven by mutated stem cell gene • Driven by misdirected immune antibodies • Neoplastic megakaryocytes produce scars • Healthy bone marrow irritated by immune cells • Does NOT easily reverse with pills • FREQUENTLY REVERSES with immune treatment • Splenomegaly usually massive • Spleen usually normal or mildly enlarged • Iron high mainly from transfusions • Iron high from transfusions + "locked in vaults" ``` ### What Does This Constellation Mean? When a loved one is told they have "myelofibrosis" that is **negative for the `JAK2` mutation**, with a history of **suspected lupus (SLE)** and **"a lot of iron built up"**, it is completely understandable for family members to feel overwhelmed. In medical terminology: 1. **"Myelofibrosis" is a description of scarring, not an automatic death sentence:** The suffix *-fibrosis* means fibrous scar tissue, and *myelo-* refers to the bone marrow. Having myelofibrosis simply means that the soft, spongy inner core of the bones—where the body manufactures red blood cells, white blood cells, and platelets—has developed fibrous spiderweb-like scar tissue (reticulin or collagen). While primary myelofibrosis is a chronic blood cancer, myelofibrosis can also happen as a **secondary reaction** when the immune system accidentally attacks the bone marrow microenvironment. 2. **Being Negative for `JAK2` and Having a Lupus Connection is Often Very Reassuring:** Roughly 60% to 65% of classical primary blood cancer myelofibrosis is driven by a genetic mutation called `JAK2 V617F`. In primary blood cancer, the stem cells themselves are genetically abnormal and reproduce out of control. When genetic testing shows **no `JAK2` mutation**, no `CALR` mutation, and no `MPL` mutation—and the patient has a history of autoimmune features like lupus (SLE), positive antinuclear antibodies (ANA), joint pain, rashes, or autoimmune hemolytic anemia—doctors immediately investigate **Autoimmune Myelofibrosis (AIMF)**. In AIMF, the bone marrow cells are **not malignant**. They are normal cells that are caught in the crossfire of an overactive immune system. 3. **Why Did "A Lot of Iron" Build Up?** Patients and families are often alarmed when blood tests show sky-high ferritin (iron storage protein) or when a bone marrow biopsy reports heavy iron accumulation. There are two primary, well-documented scientific reasons for this in autoimmune myelofibrosis: - **Reason 1: Blood Transfusions.** When the bone marrow is temporarily scarred and unable to produce enough red blood cells, patients develop severe anemia and require packed red blood cell (PRBC) transfusions. Red blood cells are packed with iron. The human body has natural ways to absorb iron from food, but **no natural way to excrete excess iron**. Every bag of transfused blood leaves behind about 200–250 milligrams of iron. After 10 to 20 transfusions, several grams of excess iron build up in the liver, heart, and bone marrow. - **Reason 2: The Inflammatory "Iron Vault" (The Hepcidin Blockade).** In lupus and autoimmune flares, the immune system releases distress signals (especially a protein called **Interleukin-6**). These signals fool the liver into thinking the body is under attack by bacteria that want to feed on iron. In response, the liver pumps out a hormone called **hepcidin**. Hepcidin acts like a security guard that locks every iron gate (**ferroportin**) in the body. The clean-up cells of the bone marrow (macrophages) continue swallowing up old, worn-out red blood cells, but they **cannot release the iron back into the bloodstream**. - Consequently, iron gets trapped inside bone marrow storage cells like gold locked in a bank vault. Blood tests show massive **ferritin** levels, yet the red-blood-cell factories inside the marrow cannot touch that iron to make new blood! This is called "iron-restricted anemia" or anemia of chronic inflammation. 4. **The Most Important Difference: Reversibility and Hope:** In classical blood-cancer myelofibrosis, the scar tissue is notoriously stubborn and almost never goes away completely with standard pills. In **Autoimmune Myelofibrosis**, however, medical literature demonstrates that **the bone marrow scarring can actually heal and reverse**! When doctors treat the underlying immune confusion using anti-inflammatory and immune-calming medications—such as corticosteroids (prednisone), rituximab, or mycophenolate—the misdirected immune attack halts. Over the course of 3 to 12 months, the bone marrow clean-up mechanisms dissolve the scar tissue, the iron can be mobilized or safely managed with iron-clearing medicines (chelation), and the bone marrow frequently regains its natural ability to produce healthy blood cells without needing transfusions. --- ## 2. Clinical & Histopathologic Foundations: Primary vs. Secondary AIMF Autoimmune Myelofibrosis (AIMF) represents an under-recognized, clinicopathologically distinct reactive myelopathy characterized by bone marrow reticulin fibrosis, peripheral blood cytopenias, and circulating autoantibodies in the absence of a clonal myeloid neoplasm. ``` AUTOIMMUNE MYELOFIBROSIS (AIMF) │ ┌───────────────────────┴───────────────────────┐ ▼ ▼ PRIMARY AIMF (pAIMF) SECONDARY AIMF (sAIMF) • Diffuse reticulin fibrosis (MF 1-3) • Diffuse reticulin fibrosis (MF 1-3) • Positive autoantibodies (ANA, DAT, RF) • Fully established autoimmune disease: • Lacks diagnostic criteria for a defined - Systemic Lupus Erythematosus (SLE, ~50-60%) systemic connective tissue disorder - Sjögren's Syndrome (~10-15%) • Isolated immune marrow failure - Evans Syndrome / Coombs+ AIHA • Highly steroid-responsive - Undifferentiated Connective Tissue Disease (UCTD) - Rheumatoid Arthritis, Systemic Sclerosis ``` ### Chronological Evolution of Diagnostic Recognition 1. **Paquette et al. (1994, *Medicine*):** First codified "autoimmune myelofibrosis" as a steroid-responsive cause of bone marrow failure associated with systemic lupus erythematosus, demonstrating that marrow fibrosis in SLE is reactive, non-malignant, and capable of complete histological regression upon corticosteroid administration (*Paquette RL et al., Medicine [Baltimore]* 1994;73(3):145–52). 2. **Bass, Pullarkat, Feinstein, and Brynes (2001, *Am J Clin Pathol*; 2003, *Am J Hematol*):** Formally defined **Primary Autoimmune Myelofibrosis (pAIMF)** as a distinct entity occurring in patients with positive autoantibodies and marrow fibrosis who did *not* meet American College of Rheumatology (ACR) criteria for a defined connective tissue disease. They established the foundational histopathologic criteria emphasizing the lack of megakaryocytic atypia, absence of osteosclerosis, and presence of polyclonal lymphoid aggregates (*Pullarkat V et al., Am J Hematol* 2003;72(1):8–12). 3. **Vergara-Lluri et al. (2014, *Human Pathology*):** Published an expanded series of 29 patients detailing the precise architectural and morphometric features that separate primary and secondary AIMF from Primary Myelofibrosis (PMF), establishing that megakaryocyte density and nuclear contours are the definitive microscopic arbiters (*Vergara-Lluri ME et al., Hum Pathol* 2014;45(11):2183–91). 4. **Piatek et al. (2017, *Acta Haematologica*):** Characterized the long-term clinical trajectory of AIMF, documenting that cytopenias resolve in the majority of patients receiving immunosuppression and that leukemic transformation does not occur in true non-clonal AIMF (*Piatek CI et al., Acta Haematol* 2017;138(3):129–37). 5. **Mertz et al. (2021, *Haematologica*):** A nationwide French multicenter study of 30 cases confirmed a 4:1 female predominance, median age of 37 years, high SLE/Sjögren's association, and prompt response to glucocorticoids, while underscoring that chronic glucocorticoid-related toxicity necessitates steroid-sparing agents like rituximab and mycophenolate (*Mertz P et al., Haematologica* 2021;106(2):617–20). 6. **Gangat, Reichard, Orazi, and Tefferi (Mayo Clinic, 2024, *British Journal of Haematology*):** In a definitive cohort of 22 patients evaluated by leading MPN and hematopathology authorities, the authors confirmed: - Median age: **45 years** (range 18–79; 77% female). - Concurrent autoimmune disease present in **83%** of patients (SLE, Evans syndrome, Sjögren's, Hashimoto's, systemic sclerosis). - High cytopenic burden: **32% pancytopenic**, **59% transfusion-dependent**. - Zero clonal driver mutations: **100% negative for `JAK2 V617F`** ($n=18$), `CALR`, and `MPL` ($n=12$). - High response rates: **74% overall complete response (CR)**, with **rituximab salvage yielding an 80% CR (4 of 5 patients)** in steroid-refractory disease (*Gangat N, Reichard K, Orazi A, Tefferi A. Br J Haematol* 2024;205(3):838–44). --- ### Formal Diagnostic Criteria Matrix (Pullarkat / Vergara-Lluri / Mayo 2024 Consensus) To establish a verified diagnosis of Autoimmune Myelofibrosis, a patient must satisfy all mandatory major criteria and exhibit autoimmune laboratory or clinical features without fulfilling criteria for a clonal myeloproliferative neoplasm or myelodysplastic syndrome: | Diagnostic Domain | Mandatory Criteria for AIMF | Pathologic & Laboratory Corroboration | | :--- | :--- | :--- | | **1. Bone Marrow Fibrosis** | **Diffuse reticulin fibrosis** (European Consensus Grade **MF-1, MF-2, or MF-3**). | Reticulin silver impregnation (Gomori or Gordon-Sweet stain) confirms fine or coarse fiber meshwork; collagen trichrome staining is typically minimal/absent. | | **2. Megakaryocyte Architecture** | **Absence of dense clustering; absence of marked atypia.** | Megakaryocytes are normal in size, small, or hypolobated; scattered evenly throughout intertrabecular marrow spaces. **Crucially lacks** the giant, cloud-like, hyperchromatic, tightly clustered sheets pathognomonic of PMF. | | **3. Non-Erythroid / Non-Myeloid Skewing** | **Absence of morphologic dysplasia; absence of panmyelosis.** | Orderly trilineage hematopoiesis; absence of granulocytic hyperplasia with basophilia or eosinophilia; absence of dysplastic micromegakaryocytes or Pelger-Huët anomalies. | | **4. Lymphoid Infiltration** | **Presence of prominent polyclonal lymphoid aggregates.** | Non-paratrabecular, well-circumscribed interstitial lymphoid aggregates consisting of mixed **$\text{CD3}^+$ T cells** and **$\text{CD20}^+$ B cells** without light-chain ($\kappa/\lambda$) restriction. | | **5. Bone Trabeculae** | **Absence of osteosclerosis.** | Cortical and trabecular bone architecture is preserved; absence of irregular woven new bone formation or appositional osteoid deposition typical of advanced PMF. | | **6. Splenomegaly** | **Absence of massive splenomegaly.** | Spleen is normal in size or only mildly/borderline enlarged due to immune clearance/hemolysis; absence of massive splenic extramedullary hematopoiesis. | | **7. Clonal Genomics** | **Definitive absence of clonal myeloid mutations and abnormal cytogenetics.** | Negative for `JAK2 V617F`, `JAK2` exon 12, `CALR` exon 9, and `MPL W515/S505`. Extended myeloid NGS panels show **zero high-molecular-risk (HMR) mutations** (`ASXL1`, `SRSF2`, `U2AF1`, `EZH2`, `IDH1/2`, `TET2`, `TP53`, `RUNX1`). Karyotype is normal diploid (46,XX or 46,XY). | | **8. Autoimmune Serology / Disease** | **Documentation of systemic autoantibodies or clinical autoimmune disease.** | Positive **ANA** (homogeneous, speckled, or nucleolar), **anti-dsDNA**, **anti-Ro/SSA**, **anti-La/SSB**, positive Direct Antiglobulin Test (**DAT / Coombs**), Rheumatoid Factor (RF), or anti-phospholipid antibodies; or formal ACR/EULAR diagnosis of SLE, Sjögren's, or UCTD. | --- ## 3. The Diagnostic Trap: AIMF vs. Triple-Negative PMF vs. MDS with Fibrosis Misdiagnosing Autoimmune Myelofibrosis is one of the most perilous errors in clinical hematology. Because both conditions present with marrow fibrosis, peripheral cytopenias, and a "dry tap" on bone marrow aspiration, community pathologists and oncologists frequently confuse non-clonal AIMF with **Triple-Negative Primary Myelofibrosis (TN-PMF)** or **Myelodysplastic Syndrome with Fibrosis (MDS-F)**. ``` THE DIAGNOSTIC TRAP │ ┌──────────────────────────────────┼──────────────────────────────────┐ ▼ ▼ ▼ AUTOIMMUNE MF (AIMF) TRIPLE-NEGATIVE PMF (TN-PMF) MDS WITH FIBROSIS (MDS-F) • Non-clonal (NGS clean) • Clonal (~80-90% HMR mutations) • Clonal (MDS driver hits) • Megas: scattered, normal/hypo • Megas: dense sheets, cloud-like • Megas: micromegakaryocytes • Polyclonal lymphoid islands • No benign lymphoid aggregates • Prominent multilineage dysplasia • Spleen normal or mild • Massive splenomegaly • Spleen normal to mild • Reverses on immunotherapy • Refractory / transplant indicated • Progresses to secondary AML • HIGHLY CURABLE / REVERSIBLE • DISMAL PROGNOSIS (OS ~2.3-3 yrs) • POOR OUTCOMES (HMAs / allo-HSCT) ``` ### Comprehensive Comparative Histopathology & Molecular Matrix | Parameter | Autoimmune Myelofibrosis (AIMF) | Clonal Triple-Negative PMF (TN-PMF) | MDS with Fibrosis (MDS-F) | | :--- | :--- | :--- | :--- | | **Primary Etiology** | Non-neoplastic, immune-mediated fibroblastic stimulation via autoantibodies & cytokine release. | Clonal stem cell neoplasm with uncharacterized or non-canonical driver lesions activating JAK-STAT. | Clonal stem cell neoplasm with multilineage myelodysplasia and secondary reactive stromal reticulin. | | **Median Patient Age** | **37 – 45 years** (peak in young to middle-aged adults). | **65 – 72 years** (peak in elderly adults). | **68 – 75 years** (predominantly elderly). | | **Sex Ratio** | **Strong Female Predominance** (~75% – 80% F). | **Male Predominance** (~60% M). | **Male Predominance** (~65% M). | | **Megakaryocyte Morphology** | Normal to small size, normal lobulation or mild hypolobation; **zero bizarre pleomorphism**. | Marked pleomorphism, giant cells, hyperchromatic **cloud-like / bulbous nuclei** with abnormal chromatin. | Frequent **dwarf / micromegakaryocytes** with single hypolobated or separated multinucleated round nuclei. | | **Megakaryocyte Distribution** | **Scattered uniformly**; loose interstitial distribution; **no dense clustering**. | **Dense cohesive clusters**, large sheets; intrasinusoidal and paratrabecular mislocalization. | Loose or clustered, often abutting trabeculae; dysplastic micromegakaryocytic aggregates. | | **Lymphoid Aggregates** | **Frequent (~60–80%)**, well-circumscribed, polyclonal mixed $\text{CD3}^+$ T / $\text{CD20}^+$ B aggregates. | Rare or absent; reactive lymphoid follicles are not a feature of PMF. | Infrequent; occasionally non-specific reactive T-cell infiltrates. | | **Fibrosis Type & Grade** | Reticulin fibrosis (**MF-1 to MF-3**); **collagen trichrome deposition and osteosclerosis typically absent**. | Progressive reticulin and **dense collagen fibrosis** (**MF-2 to MF-3**) with appositional **osteosclerosis**. | Diffuse reticulin (**MF-2 to MF-3**); collagen may be present; osteosclerosis is unusual. | | **Erythroid / Myeloid Lines** | Normoblastic erythropoiesis, orderly myeloid maturation; **zero clonal dysplasia**. | Myeloid hyperplasia with left-shift; atypical eosinophilia or basophilia; extramedullary seeding. | Marked **multilineage dysplasia** (erythroid megaloblastoid changes, ring sideroblasts, Pelger-Huët). | | **Bone Marrow Blasts** | **Normal (<2% – 5%)**; absence of immunophenotypic aberrant blast expansion. | Variable (<5% in chronic phase); can evolve to accelerated ($\ge 10\%$) or blast phase ($\ge 20\%$). | Often elevated (**5% – 19%**), defining MDS with excess blasts (MDS-EB-1/2). | | **Peripheral Blood Smear** | Mild normocytic anemia; leukopenia or thrombocytopenia; **mild or absent dacrocytes (teardrops)**. | Severe **leukoerythroblastosis**; abundant dacrocytes; circulating myelocytes, nucleated RBCs, giant platelets. | Macrocytic anemia; dysplastic neutrophils; variable teardrop poikilocytosis; circulating blasts. | | **Splenomegaly** | **Absent or mild** (spleen span $<14\text{ cm}$; palpated in $<20\%$ of cases). | **Marked to Massive** (frequently extending into left lower quadrant / pelvis via extramedullary hematopoiesis). | Absent or mild/moderate; massive splenomegaly is rare in isolated MDS-F. | | **Systemic Symptoms** | Autoimmune manifestations: arthralgias, malar rash, serositis, Raynaud's, photosensitivity, dry eyes/mouth. | Hypermetabolic **B-symptoms**: drenching night sweats, profound fatigue, cachexia, unintentional weight loss. | Fatigue, recurrent infections, bleeding diathesis, transfusion-related iron toxicity symptoms. | | **Somatic Molecular NGS** | **100% Wild-Type** for `JAK2`, `CALR`, `MPL`. **Zero HMR mutations** (`ASXL1`, `SRSF2`, `TET2`, etc.). | **Negative** for `JAK2/CALR/MPL`, BUT **~80%–90% carry clonal HMR mutations** (`ASXL1`, `SRSF2`, `U2AF1`, `EZH2`). | Clonal mutations in **RNA splicing** (`SF3B1`, `SRSF2`, `U2AF1`), epigenetic modifiers (`TET2`, `DNMT3A`, `ASXL1`), or `TP53`. | | **Cytogenetics** | **Normal diploid karyotype** (46,XX or 46,XY); absence of recurring clonal translocations. | High rate of clonal cytogenetic lesions: `del(20q)`, `+8`, `del(13q)`, `-7/del(7q)`, complex karyotype. | Typical MDS aberrations: `del(5q)`, `-7/del(7q)`, `+8`, `del(20q)`, complex/monosomal karyotypes. | | **Autoimmune Serology** | **Positive** (ANA $\ge 1:160$, anti-dsDNA, anti-SSA/Ro, anti-SSB/La, Coombs/DAT+, RF+, anti-histone). | Negative (or non-specific low-titer ANA in elderly patients without clinical autoimmune disease). | Generally negative; non-specific immune phenomena in a minority. | | **Response to Immunotherapy** | **Rapid, dramatic reversal** (70%–80% complete response to steroids, rituximab, mycophenolate). | **Refractory** to immunosuppression; steroids fail to clear fibrosis or restore counts. | Steroids ineffective; requires hypomethylating agents (azacitidine, decitabine) or luspatercept. | | **Prognosis & Survival** | **Excellent long-term overall survival**; normal life expectancy once autoimmune driver is managed. | **Dismal** (median OS **2.3 to 3.0 years** without allo-HSCT; high risk of AML transformation). | Guarded (median OS **1.5 to 3.0 years**; high risk of transformation to acute myeloid leukemia). | --- ### The Clinical Catastrophe of Misclassification 1. **If AIMF is Misdiagnosed as Triple-Negative PMF:** - **Toxicity without Efficacy:** The patient is prescribed expensive Type I JAK inhibitors (ruxolitinib, fedratinib, pacritinib) at \$15,000–\$20,000/month. Because AIMF is driven by polyclonal immune inflammation rather than constitutive `JAK2` kinase signaling, JAK inhibitors fail to eliminate the pathogenic B-cell clones, while their on-target inhibition of wild-type `JAK2` in healthy erythroid precursors severely **worsens the patient's anemia and thrombocytopenia**, accelerating transfusion dependence! - **Catastrophic Transplant Morbidity:** Believing the patient has high-risk Triple-Negative PMF (with its 2.5-year median survival), the clinician rapidly initiates an allogeneic hematopoietic stem cell transplant (allo-HSCT) workup. Subjecting an autoimmune patient with a fully reversible reactive marrow to myeloablative conditioning incurs a **20% to 35% non-relapse mortality (NRM)** risk from graft failure, sinusoidal obstruction syndrome, and fatal Graft-versus-Host Disease (GVHD)—for a condition that could have been cured with \$20 worth of oral prednisone or four infusions of rituximab. - **Withholding Curative Immunotherapy:** While undergoing futile hematology treatments, the patient's underlying autoimmune process (e.g., lupus nephritis, vasculitis, cerebritis) remains untreated, risking irreversible end-organ damage. 2. **If Clonal PMF or MDS-F is Misdiagnosed as AIMF:** - **Futile Immunosuppression:** The patient is subjected to prolonged high-dose corticosteroid tapers and immunosuppressants (cyclosporine, mycophenolate), causing steroid-induced osteonecrosis, diabetes, severe opportunistic fungal/viral infections, and sepsis. - **Delayed Curative Window:** The clonal stem cell neoplasm continues its unhindered genomic progression, acquiring secondary subclonal hits (`TP53`, `RUNX1`, `NRAS`) and progressing into blast-phase acute myeloid leukemia (secondary AML / MPN-BP), permanently closing the window of fitness required for curative allogeneic transplant. --- ## 4. The Iron Overload, Hyperferritinemia & Hepcidin Axis in AIMF & Non-`JAK2` MF A patient presenting with autoimmune-spectrum non-`JAK2` myelofibrosis who has accumulated "a lot of iron" exhibits a pathophysiological convergence of two distinct but synergistic mechanisms: **transfusional hemosiderosis** and **inflammation-induced macrophage iron sequestration**. ``` THE DUAL IRON OVERLOAD AXIS │ ┌───────────────────────────────┴───────────────────────────────┐ ▼ ▼ MECHANISM 1: TRANSFUSIONAL MECHANISM 2: INFLAMMATORY HEMOSIDEROSIS HEPCIDIN-FERROPORTIN BLOCK • Severe anemia (AIHA, PRCA, marrow fibrosis) • Autoimmune cytokines: IL-6, IL-1β, IFN-γ • Chronic PRBC transfusions (59% in Mayo cohort) • Hepatic IL-6/STAT3 transactivates HAMP (hepcidin) • Each unit adds ~200-250 mg elemental iron • Hepcidin degrades ferroportin-1 (SLC40A1) • Zero physiological excretion pathway • Macrophages CANNOT export recycled iron • Iron deposits in myocardium, liver, endocrine • Iron trapped in bone marrow histiocytes (3-4+) • Generates toxic reactive oxygen species (ROS) • Serum ferritin surges (>1,000-10,000 ng/mL) • Requires Iron Chelation (Deferasirox / Deferoxamine) • Circulating serum iron stays low (iron-restricted) ``` ### Mechanism A: Transfusional Iron Overload (Secondary Hemosiderosis) 1. **The Iron Inflow Equation:** Normal human iron physiology is closed and conservative: dietary absorption matches obligate daily sloughing (enterocytes, skin, sweat) at approximately **1.0 to 2.0 mg/day**. Humans possess **no active physiological mechanism to excrete excess iron**. Each unit of packed red blood cells (PRBCs, ~300 mL) delivers approximately **200 to 250 mg of elemental iron**. 2. **Kinetics of Tissue Saturation:** In patients with autoimmune myelofibrosis, severe immune cytopenias (autoimmune hemolytic anemia / Evans syndrome, pure red cell aplasia, or marrow compression) frequently induce profound transfusion dependence. In the Mayo Clinic series (*Gangat et al., 2024*), **59% of patients required chronic RBC transfusions**. - After receiving **10 to 20 units of blood**, cumulative exogenous iron intake reaches **2.0 to 5.0 grams**—effectively doubling total normal body iron stores (~3.5–4.0 g in adults). - Circulating **transferrin** (normal saturation 20%–45%) becomes completely saturated (**Transferrin Saturation [TSAT] $>50\% - 80\%+$**). - Once transferrin capacity is overwhelmed, unbound iron enters the plasma as **Non-Transferrin-Bound Iron (NTBI)** and its chemically reactive fraction, **Labile Plasma Iron (LPI)**. 3. **Parenchymal & Bone Marrow Toxicity:** - **Cellular Influx:** LPI readily enters parenchymal cells of the liver (hepatocytes), heart (cardiomyocytes), and endocrine organs (pituitary, pancreas) via non-regulated divalent metal transporters (such as L-type calcium channels and ZIP14), triggering Fenton and Haber-Weiss reactions: $$\text{Fe}^{2+} + \text{H}_2\text{O}_2 \longrightarrow \text{Fe}^{3+} + \text{OH}^\bullet + \text{OH}^-$$ - **Hydroxyl Radicals ($\text{OH}^\bullet$):** Drive lipid peroxidation of organelle membranes, mitochondrial DNA damage, and progressive organ dysfunction (cardiac arrhythmias, systolic heart failure, hepatic cirrhosis, bronze diabetes, hypogonadism). - **Bone Marrow Suppression:** Within the marrow microenvironment itself, toxic intracellular iron and oxidative stress directly suppress surviving hematopoietic stem and progenitor cells (BFU-E, CFU-GM), exacerbating baseline ineffective erythropoiesis. 4. **Therapeutic Iron Chelation (Deferasirox / Deferoxamine):** - In patients who accumulate transfusional iron, oral iron chelation therapy (such as **deferasirox** [*Exjade* / *Jadenu*]) or subcutaneous/IV **deferoxamine** binds circulating NTBI and tissue iron, promoting fecal and urinary excretion. - **Hematologic Improvement Phenomenon:** In multiple prospective and registry studies of lower-risk myelodysplastic syndromes and myelofibrosis (e.g., the *TELESTO* trial; Badawi et al.; List et al.), iron chelation with deferasirox produced unexpected **erythroid hematologic improvements (HI-E)** in 15% to 30% of transfusion-dependent patients—occasionally yielding transfusion independence. Reducing marrow oxidative stress restores residual stem-cell viability and diminishes the paracrine inflammatory loop. --- ### Mechanism B: Hyperferritinemia & Reticuloendothelial Iron Trapping (The Hepcidin Axis) Crucially, an autoimmune patient can exhibit **massive iron buildup and hyperferritinemia even prior to extensive transfusions**, driven by the inflammatory molecular cascade governing human iron distribution: ``` [SLE / Autoimmune Flare: Activated T & B Cells, Macrophages] │ ▼ Secretes Proinflammatory Cytokines [IL-6, IL-1β, IFN-γ] │ ▼ Binds to IL-6R / gp130 on Hepatocytes [JAK1/2 - STAT3 Phosphorylation Cascade] │ ▼ Transactivates HAMP Gene Transcription [Excess Hepcidin Secretion (Master Hormone)] │ ▼ Binds Ferroportin-1 (SLC40A1) Channels [Internalization & Lysosomal Degradation of Ferroportin] │ ┌─────────────────────┴─────────────────────┐ ▼ ▼ [Duodenal Enterocytes] [Bone Marrow Macrophages] Absorptive channels destroyed; CANNOT export iron recycled from Dietary iron absorption blocked phagocytosed red blood cells (~20-25 mg/day) │ ▼ [IRON TRAPPED INSIDE MARROW] • Coarse Hemosiderin on Prussian Blue (3-4+) • Sky-High Serum Ferritin (>1,000-10,000 ng/mL) • Low Circulating Serum Iron (<30-50 µg/dL) • Absent Sideroblasts (Starved Erythroid Precursors) ``` 1. **The Hepcidin Synthesis Cascade:** - In active Systemic Lupus Erythematosus (SLE), Undifferentiated Connective Tissue Disease (UCTD), and Autoimmune Myelofibrosis, immune complexes and activated autoreactive lymphocytes generate massive systemic release of **Interleukin-6 ($\text{IL-6}$)**, $\text{IL-1}\beta$, and $\text{IFN-}\gamma$. - $\text{IL-6}$ binds to hepatic IL-6 receptor / gp130 complexes, triggering phosphorylation of **Janus kinase 1/2 (JAK1/JAK2)** and **Signal Transducer and Activator of Transcription 3 (STAT3)**. - Phosphorylated STAT3 homodimers translocate to the hepatocyte nucleus, binding directly to the promoter of the **$HAMP$ gene**, driving hyper-secretion of the 25-amino acid peptide hormone **hepcidin**. 2. **Ferroportin Internalization and Reticuloendothelial Blockade:** - Hepcidin is the master systemic iron gatekeeper. It binds with high affinity to **ferroportin-1 ($SLC40A1$)**, the sole recognized cellular iron exporter expressed on duodenal enterocytes, hepatocytes, and reticuloendothelial macrophages (Kupffer cells in the liver, splenic histiocytes, and bone marrow stromal macrophages). - Hepcidin binding induces ubiquitination, endocytosis, and lysosomal degradation of ferroportin. - **The Consequence in the Bone Marrow:** Reticuloendothelial macrophages ingest senescent red blood cells daily, recycling approximately **20 to 25 mg of elemental iron** from heme catabolism via heme oxygenase-1 ($\text{HO-1}$). Under normal conditions, ferroportin exports this iron back to plasma transferrin. When ferroportin is destroyed, **macrophages cannot release a single atom of iron**. 3. **Histopathology & Laboratory Corroboration:** - **Prussian Blue (Perls') Iron Staining:** Bone marrow biopsy reveals **$3+$ to $4+$ coarse hemosiderin storage** packed densely inside marrow histiocytes. Pathologists observing this stain routinely document "heavily increased bone marrow iron stores." - **The Sideroblast Deficit:** Simultaneously, because iron cannot exit macrophages to reach erythroblast transferrin receptors ($\text{CD71}$), developing erythroid precursors are completely starved of iron. Prussian blue staining reveals **zero or markedly depleted sideroblasts** (developing red cells containing cytoplasmic iron granules). - **Serum Iron Panel Paradox:** - **Serum Ferritin:** Markedly elevated (**1,000 to $>10,000\text{ ng/mL}$**), driven jointly by intracellular ferritin leaking from iron-choked macrophages and direct transcriptional induction of ferritin heavy chain ($\text{FTH1}$) by inflammatory cytokines ($\text{IL-1}\beta$, $\text{TNF-}\alpha$) as an acute-phase reactant. - **Serum Iron:** Paradoxically **profoundly low ($<30\text{ }\mu\text{g/dL}$)**. - **Transferrin Saturation (TSAT):** Low or low-normal ($<15\% - 20\%$), confirming **functional iron deficiency / iron-restricted erythropoiesis**. 4. **The Macrophage Activation Syndrome (MAS) / Secondary HLH Spectrum:** - In severe SLE or autoimmune flares, this macrophage-iron axis can escalate into **Macrophage Activation Syndrome (MAS)**, a form of secondary hemophagocytic lymphohistiocytosis (sHLH). - Characterized by extreme hyperferritinemia (often exceeding **$5,000 - 50,000+\text{ ng/mL}$**), worsening pancytopenia, coagulopathy (hypofibrinogenemia), hypertriglyceridemia, and morphologic **hemophagocytosis** (macrophages actively engulfing intact erythrocytes, platelets, and leukocytes within the bone marrow core). --- ### Mechanism C: Genetic & Phenotypic Differential Overlaps When evaluating an ambiguous case of non-`JAK2` myelofibrosis with marked iron buildup, clinicians must rule out or identify two critical co-occurring modifiers: 1. **Hereditary Hemochromatosis ($HFE$) Co-Inheritance:** - The primary genetic variants causing hereditary hemochromatosis—**$HFE\text{ C282Y}$** (exon 4 substitution) and **$HFE\text{ H63D}$** (exon 2 substitution)—have high carrier frequencies in European-ancestry populations (~10%–15% heterozygous carriers). - In patients who inherit heterozygous or compound heterozygous $HFE$ variants alongside an autoimmune disorder, mutated HFE fails to properly associate with transferrin receptor 1 ($\text{TFR1}$) and ALK3/BMP pathways, causing baseline inappropriate downregulation of hepcidin and **hyper-absorption of dietary iron**. - When such patients develop autoimmune anemia and receive transfusions, their rate of toxic parenchymal iron accumulation accelerates dramatically compared to wild-type individuals. 2. **$SF3B1$ Spliceosome Mutation & Ring Sideroblasts (MDS-RS / MDS/MPN-RS-T):** - In older adults presenting with non-`JAK2` cytopenias and high marrow iron, bone marrow aspirates must be carefully stained with Prussian blue to distinguish between **macrophage iron storage** and **ring sideroblasts**. - Mutations in the core spliceosome gene **$SF3B1$** (most commonly `K700E`, `E622D`, `R625C`, `K666N`) disrupt alternative splicing of mitochondrial iron chaperone **$ABCB7$**, causing abnormal mitochondrial iron accumulation that rings $\ge 15\%$ of the nucleus in developing erythroid cells. - Ring sideroblast disorders represent clonal myeloid neoplasms (MDS-RS or MDS/MPN with ring sideroblasts and thrombocytosis). Demonstrating the absence of $SF3B1$ mutations on myeloid NGS and the absence of perinuclear ringed sideroblasts confirms that iron accumulation is reticuloendothelial/inflammatory (AIMF) rather than mitochondrial/clonal. --- ## 5. Evidence-Based Therapeutic Protocols & Response Dynamics Unlike clonal myeloproliferative neoplasms, where treatment is predominantly palliative (cytoreduction, spleen shrinkage, symptom control), **Autoimmune Myelofibrosis is a highly treatable, frequently reversible condition**. ``` EVIDENCE-BASED THERAPEUTIC CASCADE │ ▼ [FIRST-LINE THERAPY: CORTICOSTEROIDS ± STEROID-SPARING AGENT] • Prednisone 1.0 mg/kg/day PO (or IV Methylprednisolone pulses 500-1000 mg/day x 3 days) • Add early steroid-sparing agent (Mycophenolate Mofetil 1-2 g/day OR Cyclosporine 3-5 mg/kg/day) • Expected Response: 50% - 54% Complete Response (CR) within 4 to 8 weeks │ ┌────────────────────┴────────────────────┐ ▼ ▼ [COMPLETE RESPONSE (CR)] [STEROID REFRACTORY / RELAPSE] • Cytopenias resolve • Cytopenias persist after 4-6 wks • Transfusions stop • Intolerable glucocorticoid toxicity • Slow steroid taper over 3-6 mos • Relapse during steroid tapering • Fibrosis regresses (MF 0-1) │ ▼ [SALVAGE THERAPY: RITUXIMAB] • Anti-CD20 mAb: 375 mg/m² IV weekly x 4 (or 1,000 mg IV on Days 1 and 15) • Mayo Clinic 2024 Series: 80% CR (4/5) • Curbs pathogenic autoantibody secretion • Resolves bone marrow reticulin meshwork ``` ### Frontline Immunosuppressive Protocols 1. **Systemic Glucocorticoids (First-Line Standard of Care):** - **Regimen:** Oral **prednisone** at **$1.0\text{ mg/kg/day}$** (based on ideal body weight) for 4 to 6 weeks. In patients with acute, severe, life-threatening cytopenias (Hb $<7.0\text{ g/dL}$, platelets $<20 \times 10^9/\text{L}$) or concurrent autoimmune hemolytic anemia/Evans syndrome, initial therapy begins with intravenous **pulse methylprednisolone** ($500\text{ to }1,000\text{ mg/day}$ IV for 3 consecutive days), followed by oral prednisone. - **Response Kinetics:** Hematologic response typically manifests within **2 to 4 weeks**, marked by a brisk reticulocyte surge, rising hemoglobin, platelet stabilization, and immediate cessation of transfusion requirements. Complete hematologic response (CR) is achieved in **50% to 54%** of frontline patients (*Mertz et al., 2021; Gangat et al., 2024*). - **Tapering Protocol:** Once peripheral counts normalize (typically Week 6–8), prednisone is tapered gradually by $5\text{ to }10\text{ mg}$ every 2 weeks down to $20\text{ mg/day}$, then by $2.5\text{ to }5\text{ mg}$ every 2 to 4 weeks toward complete discontinuation over 3 to 6 months. 2. **Early Steroid-Sparing Agents:** Because prolonged glucocorticoid administration causes severe morbidity (aseptic necrosis of the femoral head, osteoporosis, steroid-induced diabetes, Cushingoid disfigurement, opportunistic pneumocystis/fungal infections), modern consensus recommends introducing steroid-sparing immunosuppressants early: - **Mycophenolate Mofetil (MMF, *CellCept*):** $1,000\text{ to }2,000\text{ mg/day}$ orally in two divided doses. MMF selectively inhibits inosine monophosphate dehydrogenase (IMPDH), arresting de novo guanosine synthesis and suppressing autoreactive T- and B-cell proliferation. Yields ~50% CR rate with excellent tolerability in lupus-associated AIMF. - **Cyclosporine A (*Neoral*):** $3.0\text{ to }5.0\text{ mg/kg/day}$ orally, targeting trough blood levels of $100\text{ to }200\text{ ng/mL}$. Calcineurin inhibition suppresses nuclear factor of activated T-cells (NFAT) dephosphorylation, silencing $\text{IL-2}$ transcription. Yields ~50% CR rate in steroid-dependent cytopenic marrow failure. - **Hydroxychloroquine (*Plaquenil*):** $200\text{ to }400\text{ mg/day}$ orally (maximum $5.0\text{ mg/kg}$ actual weight/day) should be maintained as baseline background therapy in all patients with confirmed or suspected lupus/connective tissue disease to reduce systemic disease flares and thrombotic risk. --- ### Second-Line & Salvage Therapy: Rituximab (Anti-CD20) For patients who fail to achieve a complete hematologic response after 4 to 6 weeks of corticosteroids, who relapse during steroid tapering, or who cannot tolerate steroid toxicity, **targeted B-cell depletion with rituximab is the gold-standard salvage intervention**: - **Mechanism of Action:** Rituximab is a chimeric IgG1 monoclonal antibody targeting the extracellular **$\text{CD20}$ surface antigen** expressed on pre-B and mature B lymphocytes. In AIMF, rituximab eliminates the autoreactive B-cell clones that produce anti-erythrocyte/anti-platelet autoantibodies and silences B-cell-derived profibrotic cytokines ($\text{TGF-}\beta$, $\text{IL-6}$), allowing bone marrow mesenchymal stromal cells to deactivate. - **Dosing Schedules:** - *Lymphoma Schedule:* $375\text{ mg/m}^2$ IV infusion once weekly for 4 consecutive weeks (Weeks 1, 2, 3, 4). - *Rheumatoid Arthritis / Lupus Schedule:* $1,000\text{ mg}$ IV infusion on Day 1 and Day 15 (repeated at 6 months if necessary). - **Mayo Clinic 2024 Clinical Trial / Registry Evidence:** In the landmark Mayo Clinic cohort (*Gangat, Reichard, Orazi, & Tefferi, Br J Haematol 2024*), rituximab salvage achieved an extraordinary **80% Complete Response rate (4 out of 5 evaluable refractory patients)**, demonstrating successful resolution of transfusion dependence and reversal of bone marrow failure where conventional immunosuppressants had failed. - **Intravenous Immunoglobulin (IVIG):** $1.0\text{ g/kg/day}$ IV for 2 consecutive days (or $0.4\text{ g/kg/day}$ for 5 days) serves as an effective acute rescue modality to block Fc receptors on splenic and hepatic macrophages during severe autoimmune hemolytic crisis or immune thrombocytopenia while waiting for rituximab or steroids to take effect. --- ### Time Course of Objective Fibrosis Reversal One of the most profound biological phenomena in hematology is the timeline of histological healing in Autoimmune Myelofibrosis: ``` HISTOLOGICAL FIBROSIS REGRESSION TIMELINE (AIMF) Baseline: Pre-Treatment Month 1 - 2: Induction Month 3 - 6: Cellular Recovery Month 6 - 12: Architecture Cleared ┌──────────────────────┐ ┌──────────────────────┐ ┌──────────────────────┐ ┌──────────────────────┐ │ • Fibrosis Grade MF-2/3 │ • Peripheral counts │ │ • Reticulin grade │ │ • Reticulin grade │ │ • Dry Tap on Aspirate│ ───► │ begin normalizing │ ───► │ drops to MF-1 │ ───────► │ normalizes (MF-0/1)│ │ • Transfusion Dep. │ │ • Transfusions cease │ │ • Normal trilineage │ │ • Full hematopoietic │ │ • Lymphoid aggregates│ │ • Lymphoid clusters │ │ islands expand │ │ restoration │ └──────────────────────┘ │ dissolve │ └──────────────────────┘ └──────────────────────┘ └──────────────────────┘ ``` - **Month 1 to 2:** Peripheral blood counts normalize; transfusion requirements cease; inflammatory markers ($\text{ESR}$, $\text{CRP}$, $\text{IL-6}$) fall rapidly. - **Month 3 to 6:** Repeat bone marrow core biopsy demonstrates regression of reticulin fiber meshwork (European Consensus grade drops from MF-2/MF-3 down to MF-1); polyclonal lymphoid aggregates disappear; erythroid and megakaryocytic cell lines regain normal intertrabecular architecture. - **Month 6 to 12:** Complete histological resolution (Grade MF-0 or minimal MF-1); aspirate yields a normal particulate spicule preparation; patient achieves unmaintained or low-dose maintained clinical remission. --- ## 6. Pairing `JAK2 V617F+` Clonal MF + Autoimmune MF: The 3 High-Leverage Startup Wedges Pairing the flagship indication on `rare-disease-atlas.github.io` (`JAK2 V617F+` Myelofibrosis) with its non-clonal counterpart (**Autoimmune Myelofibrosis**) provides an extraordinary unfair advantage across computational biology, software-as-a-medical-device (SaMD), and public health systems. ``` THE THREE TRANSLATIONAL STARTUP WEDGES │ ┌──────────────────────────┼──────────────────────────┐ ▼ ▼ ▼ WEDGE 1 WEDGE 2 WEDGE 3 COMPUTATIONAL BIO AI DIGITAL PATHOLOGY CROSSROADS REGISTRY "Nature's Reversibility Multi-Modal SaMD Triage: Bridging Rheumatology Control Group" WSI + NGS + Autoimmune & Hematology Silos • Paired multi-omics • 30-40% community error • Captures non-JAK2 MF • scRNA-seq & Visium HD • Mega nuclear AI morph • RWE for Rituximab & • Resolving AIMF vs. density & atypia score Hepcidin drugs Non-resolving PMF • Automated risk triage • Prevents lethal • Discovers MMP switches (AIMF vs TN-PMF vs MDS) transplant/JAKi traps ``` --- ### Wedge 1: Computational Biology — "Nature's Reversibility Control Group" #### The Fundamental Bottleneck in Fibrosis Drug Discovery Fibrotic diseases—including idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH/MASH), systemic sclerosis, and primary myelofibrosis—account for an estimated **45% of all deaths in the industrialized world**. Yet, human drug development has been severely hindered by a universal biological limitation: **in adult humans, established tissue fibrosis is considered biologically irreversible**. In `JAK2 V617F+` Primary Myelofibrosis, FDA-approved kinase inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) reduce splenomegaly and alleviate constitutional symptoms, but **fewer than 10% to 15% of patients achieve even a modest 1-grade reduction in reticulin fibrosis after years of continuous therapy**. Pathologists view the collagenous scar tissue as an intractable, permanent graveyard of hematopoiesis. #### The Breakthrough Insight: AIMF as the Natural Human Experiment In **Autoimmune Myelofibrosis (AIMF)**, human bone marrow reticulin fibrosis (even high-grade MF-2 or MF-3) **regularly and completely dissolves within 3 to 12 months** under targeted immunosuppression! AIMF and `JAK2+` PMF share virtually identical downstream extracellular matrix (ECM) histopathology: dense type I, III, and IV collagen fibers crosslinked around $\text{Gli1}^+$ and $\text{LepR}^+$ bone marrow mesenchymal stromal cells (MSCs) and myofibroblasts. Yet in AIMF, the human body retains the intrinsic cellular machinery to **clear the matrix, dismantle the scar, and restore healthy hematopoiesis**. AIMF is **Nature's perfect human in vivo reversibility control group**. #### The Computational Multi-Omics Platform Strategy A seed-stage computational biology startup can validate novel antifibrotic targets at a fraction of standard preclinical discovery costs by profiling human clinical specimens: ``` COMPARATIVE MULTI-OMICS TARGET DISCOVERY │ ┌───────────────────────────┴───────────────────────────┐ ▼ ▼ RESOLVING AIMF BONE MARROW REFRACTORY JAK2+ PMF MARROW (Pre-Rx vs Month 3 vs Month 6 post-Rituximab) (Baseline vs Post-Ruxolitinib 1 yr) │ │ └───────────────────────────┬───────────────────────────┘ ▼ [SPATIAL TRANSCRIPTOMICS & scRNA-seq] (10x Genomics Visium HD / CosMx SMI) │ ┌───────────────┴───────────────┐ ▼ ▼ [STROMA REVERSAL SWITCHES] [ALARMING PATHWAYS UNVEILED] • De-differentiation of CAR / • Autonomous S100A8/A9 and Gli1+ myofibroblasts TGF-β secretion from mutant megas • Upregulated Matrix Metallo- • Chronic TIMP-1 overexpression proteinases (MMP-1, 8, 13) locking matrix degradation • Silencing of SMAD2/3 & NF-κB • Persistent persistence heterodimers ``` 1. **Longitudinal Human Tissue Cohort:** Partner with academic medical centers (e.g., Mayo Clinic, USC, French AIMF Consortium) to obtain serial pre- and post-treatment bone marrow core biopsy blocks from: - AIMF patients undergoing successful fibrosis regression on rituximab/prednisone (Baseline, Month 3, Month 6). - `JAK2 V617F+` PMF patients with persistent/worsening fibrosis on ruxolitinib. 2. **Spatial Multi-Omics Architecture:** - **High-Definition Spatial Transcriptomics:** Deploy **10x Genomics Visium HD** (2 $\mu\text{m}$ resolution) or **Nanostring CosMx Spatial Molecular Imager (SMI)** directly onto formalin-fixed paraffin-embedded (FFPE) marrow core biopsy sections. - **Cellular Neighborhood Deconvolution:** Map the spatial interactome between megakaryocytes, $\text{CD3}^+/\text{CD20}^+$ lymphoid aggregates, and $\text{LepR}^+ / \text{Gli1}^+ / \text{CXCL12}^+$ abundant reticular (CAR) stromal cells. 3. **High-Yield Biological Target Hits:** - **Stromal De-Differentiation vs. Apoptosis Program:** Determine whether resolving human stromal myofibroblasts undergo programmed senescence, apoptosis, or phenotypic reprogramming back into quiescent supportive mesenchymal stem cells. - **The Collagenase Activation Switch:** Identify the specific human matrix metalloproteinases—such as **$\text{MMP-1}$ (interstitial collagenase)**, **$\text{MMP-8}$**, and **$\text{MMP-13}$**—that are transactivated during AIMF matrix clearance, versus the endogenous tissue inhibitors of metalloproteinases (**$\text{TIMP-1}$, $\text{TIMP-2}$**) that maintain fibrotic lock-in in `JAK2+` PMF. - **Alarmin Depletion:** Quantify how rapidly clearing autoreactive B cells silences the paracrine $\text{TGF-}\beta1$, $\text{PDGF}$, and $\text{S100A8/A9}$ alarmin signals that drive fibroblast proliferation. 4. **Actionable Commercial Output:** Identify druggable master regulatory kinases, transcription factors, or GPCRs capable of pharmacologically forcing the "AIMF resolution program" inside non-resolving `JAK2+` PMF, IPF, and hepatic cirrhosis. --- ### Wedge 2: AI Digital Pathology & SaMD Diagnostic Triage Engine #### The Clinical Problem: High Community Diagnostic Discordance In community and general pathology practices—where >70% of bone marrow biopsies in the United States and EU are initially interpreted—the diagnostic discordance rate for fibrotic marrow disorders exceeds **30% to 40%**. When a general pathologist encounters reticulin silver staining showing MF-2 or MF-3 fibrosis in a cytopenic patient, their algorithmic training defaults toward "Primary Myelofibrosis." If the reference laboratory returns `JAK2 V617F` negative, the biopsy is frequently signed out as "Triple-Negative Primary Myelofibrosis," setting in motion the disastrous cascade of kinase inhibitors, cytotoxic chemotherapy, and premature transplant evaluation. #### The Software-as-a-Medical-Device (SaMD) Architecture A clinical AI startup can develop a **multi-modal, regulatory-cleared (FDA 510(k) / De Novo / CE-IVDR) Software-as-a-Medical-Device** that integrates into digital pathology whole-slide scanners (Philips Ultra Fast, Leica Aperio, Hamamatsu NanoZoomer) and laboratory information systems (Epic Beaker, Proscia Concentriq, Paige AI). ``` MULTI-MODAL SaMD DIAGNOSTIC ENGINE │ ┌─────────────────────────────────┼─────────────────────────────────┐ ▼ ▼ ▼ [IMAGE VISION MODULE] [GENOMIC FILTER MODULE] [SEROLOGY/IRON MODULE] Whole-Slide Scanning: Structured NGS Feeds: Electronic Health Record: • Reticulin WSI: fiber • JAK2/CALR/MPL screen • ANA titer & pattern density & thickness • Extended Myeloid Panel • anti-dsDNA, anti-SSA/SSB • H&E WSI: Megakaryocyte (ASXL1, SRSF2, TET2, • Direct Coombs / DAT test morphometry & clustering U2AF1, EZH2, RUNX1, TP53) • Ferritin, TSAT, Hepcidin • Lymphoid Aggregate • Karyotype / FISH inputs • Reticulocyte count, LDH classifier (T vs B mix) │ │ │ └─────────────────────────────────┼─────────────────────────────────┘ ▼ [BAYESIAN MULTI-MODAL REASONING CORE] │ ┌─────────────────┴─────────────────┐ ▼ ▼ [CLINICAL DECISION OUTPUT] [EXPLAINABLE PATHOLOGY HEATMAP] • Calibrated Probability Score: • Megakaryocyte nuclear contour masks - Autoimmune Myelofibrosis (94%) • Clustering density neighbor graphs - Triple-Negative PMF (<2%) • Lymphoid aggregate polygon boundaries - MDS with Fibrosis (<4%) • Automated Gomori reticulin scoring • Recommended Reflex Tests: - Screen anti-dsDNA & lupus panel - Check Prussian blue marrow iron - Defer JAK inhibitor & HSCT consult ``` #### Quantitative Image Features Extracted by Computer Vision: 1. **Megakaryocyte Spatial Nearest-Neighbor Metric:** - *PMF Signature:* Cohesive clustering ($\ge 3 - 6$ megakaryocytes in direct contact or within $<15\text{ }\mu\text{m}$ radius), paratrabecular margin drift. - *AIMF Signature:* Scattered, solitary distribution (inter-megakaryocyte distance $>60\text{ }\mu\text{m}$), absence of cohesive sheets. 2. **Megakaryocyte Nuclear Morphometry:** - *PMF Signature:* High nuclear-to-cytoplasmic (N:C) ratio, marked nuclear pleomorphism, hyperchromasia, convex perimeter defect score representing **cloud-like, bulbous, or "staghorn" lobulation**. - *AIMF Signature:* Normal N:C ratio, orderly multilobation, smooth nuclear membranes, normal or small cellular diameter. 3. **Lymphoid Aggregate Identification:** - Automated segmentation of nodular lymphoid aggregates; dual-channel IHC analysis confirming mixed polyclonal $\text{CD3}^+$ T cells and $\text{CD20}^+$ B cells (AIMF) versus absent lymphoid tissue or monotypic $\kappa/\lambda$ restricted B-cell clones. 4. **Peripheral Smear Dacrocyte (Teardrop Cell) Counter:** - Convolutional neural network quantifying teardrop erythrocytes per high-power field (HPF). $<2\text{ dacrocytes/HPF}$ favors AIMF; $\ge 5 - 10\text{ dacrocytes/HPF}$ with circulating nucleated red cells favors clonal PMF. #### Commercialization & Reimbursement Model - **Hospital SaaS Subscription:** Sold to pathology groups and cancer centers at \$50,000–\$150,000/year to minimize misdiagnosis malpractice liability and speed turnaround times. - **Payer Diagnostic Risk-Mitigation:** Health insurers and Medicare Advantage plans incentivize adoption via CPT Category III PLA codes. Preventing even a single unwarranted \$250,000 allogeneic transplant or unnecessary lifelong \$200,000/year JAK inhibitor regimen provides immediate 10x ROI for payers. --- ### Wedge 3: Public Health / Rare Rheumatology-Hematology Crossroads Registry #### The Clinical Silo Problem The healthcare system is functionally fractured between subspecialties: - **In Rheumatology Clinics:** When a patient with lupus, Sjögren's, or undifferentiated connective tissue disease presents with worsening cytopenias, rheumatologists frequently treat empirically with steroids or adjust baseline DMARDs. Bone marrow biopsies are **rarely performed** unless hematology is consulted, leading to significant underdiagnosis of secondary AIMF. - **In Hematology Clinics:** When a patient presents with unexplained cytopenias and a fibrotic bone marrow biopsy, hematologists are trained on oncology/MPN diagnostic pathways. If `JAK2` is negative, extended autoimmune serologies (anti-dsDNA, anti-Ro, anti-La, DAT, hepcidin) are frequently omitted or ordered only after months of confusion. - **The Crack in the System:** Non-`JAK2` cytopenic patients with unrecognized autoimmune bone marrow failure spend an average of **12 to 24 months in diagnostic limbo**, receiving repetitive blood transfusions and accumulating severe iron overload while their underlying treatable disease goes unaddressed. #### The Registry & Real-World Evidence (RWE) Opportunity Establish the **International Crossroads Registry for Autoimmune & Non-Clonal Myelopathies**: ``` CROSSROADS REGISTRY ARCHITECTURE │ ┌─────────────────────────────────┼─────────────────────────────────┐ ▼ ▼ ▼ [PATIENT IDENTIFICATION] [DE-IDENTIFIED BIOBANKING] [PHARMA / PAYER VALUE] • Non-JAK2 / TN Cytopenias • Serial FFPE marrow blocks • RWE for Label Expansion: • Refractory Anemia / AIHA • Serum hepcidin & cytokines - Rituximab in steroid-refractory • Elevated Ferritin / Iron • Peripheral blood mononuclear - Hepcidin antagonists / ALK2i • Lupus / UCTD overlaps cells (PBMCs) for scRNA-seq - Oral iron chelators (Deferasirox) • Patient-reported outcomes • Longitudinal clinical data • Payer cost-avoidance data ``` 1. **Natural History & Diagnostic Standardization:** Aggregate prospective, longitudinal clinical and genomic data on 500+ patients across 50 international rheumatology-hematology centers, codifying the definitive international diagnostic criteria and replacing outdated consensus guidelines. 2. **Real-World Evidence for Drug Repurposing & Label Expansion:** - **Rituximab:** Despite an 80% complete response rate in steroid-refractory AIMF (*Mayo Clinic, 2024*), rituximab remains off-label for this indication in the United States and Europe. Insurers routinely reject prior authorizations, delaying life-saving therapy. A rigorous RWE registry provides the definitive synthetic control arm required to achieve FDA/EMA orphan drug labeling or NCCN compendium inclusion. - **Hepcidin-Modulating Therapeutics:** Evaluate the role of emerging oral **ACVR1/ALK2 inhibitors** (e.g., momelotinib, zilurgisertib) and **anti-hepcidin monoclonal antibodies / spiegelmers** in breaking the macrophage iron-trapping cycle in patients with severe inflammatory hyperferritinemia and iron-restricted anemia. 3. **Venture Philanthropy Co-Investment:** Partner with the **Lupus Research Alliance (LRA)**, the **Leukemia & Lymphoma Society (LLS TAP)**, and the **MPN Research Foundation** to co-fund natural history registries and investigator-sponsored trials (ISTs) bridging rheumatology and hematology. --- ## 7. Platform Architecture Roadmap: Live Site & MCP Integration To seamlessly embed this clinical and translational expansion into `https://rare-disease-atlas.github.io` and the open-source agent tooling ecosystem without modifying existing live files prematurely: ``` PLATFORM INTEGRATION MAP │ ┌─────────────────────────────┼─────────────────────────────┐ ▼ ▼ ▼ [STATIC SITE INTEGRATION] [AGENT MCP TOOL EXPANSION] [OPEN DATASETS & LLMS.TXT] • New interactive submodule: • 3 new specialized tools in • Update /llms.txt with /aimf-and-iron-axis orphan-disease-opportunity- AIMF clinical definitions • Side-by-side comparison: mcp (get_aimf_criteria, • Register Hugging Face JAK2+ PMF vs AIMF triage_myelofibrosis, dataset split: • Interactive Hepcidin analyze_iron_axis) aimf-hepcidin-cohort macrophage iron simulator • Structured JSON schemas • Schema.org MedicalCondition ``` ### Static Site UX Architecture (`rare-disease-atlas.github.io`) - **Interactive Morphometry Visualizer:** An interactive slide comparison viewer displaying Gomori reticulin and H&E stains of `JAK2 V617F+` PMF (dense clustering, cloud-like megakaryocytes, osteosclerosis) versus Autoimmune Myelofibrosis (scattered hypolobated megakaryocytes, mixed lymphoid aggregates, pure reticulin), allowing students, clinicians, and researchers to toggle diagnostic heatmaps. - **The Hepcidin-Ferroportin Iron Flow Simulator:** A visual SVG-based biological diagram illustrating how $\text{IL-6}$ stimulates hepcidin, degrades ferroportin, locks iron inside macrophages, and produces high ferritin alongside iron-restricted erythropoiesis—with an interactive slider showing the effect of steroids, rituximab, or iron chelation. - **Diagnostic Triage Flowchart:** A step-by-step interactive clinical algorithm guiding users through the evaluation of non-`JAK2` cytopenic patients with bone marrow fibrosis. --- ### Open-Source MCP Server Tooling Specification To empower autonomous AI research agents (Claude Desktop, Cursor, Antigravity, Biomni) evaluating myelofibrosis cases, the `orphan-disease-opportunity-mcp` server package will expose three structured JSON tools: ```json { "tools": [ { "name": "get_aimf_diagnostic_criteria", "description": "Retrieves verified clinicopathologic diagnostic criteria for Autoimmune Myelofibrosis (AIMF) established by Pullarkat (2003), Vergara-Lluri (2014), and Mayo Clinic (2024), differentiating primary vs secondary forms.", "inputSchema": { "type": "object", "properties": { "subtype": { "type": "string", "enum": ["all", "primary_aimf", "secondary_aimf"], "default": "all" } } } }, { "name": "triage_myelofibrosis_clonality", "description": "Evaluates patient features (megakaryocyte morphometry, NGS mutations, autoimmune serology, spleen size) to calculate calibrated probability of Autoimmune Myelofibrosis vs. Triple-Negative PMF vs. MDS with Fibrosis.", "inputSchema": { "type": "object", "properties": { "jak2_mutated": {"type": "boolean"}, "calr_mutated": {"type": "boolean"}, "mpl_mutated": {"type": "boolean"}, "hmr_mutations": { "type": "array", "items": {"type": "string"}, "description": "List of clonal mutations e.g. ['ASXL1', 'SRSF2', 'TET2']" }, "megakaryocyte_clustering": { "type": "string", "enum": ["absent", "loose", "dense_sheets"] }, "megakaryocyte_atypia": { "type": "string", "enum": ["normal_or_mild", "cloud_like_bulbous", "micromegakaryocytes"] }, "lymphoid_aggregates": {"type": "boolean"}, "splenomegaly": { "type": "string", "enum": ["none", "mild", "massive_extending_pelvis"] }, "autoantibodies_positive": { "type": "array", "items": {"type": "string"}, "description": "Positive serologies e.g. ['ANA', 'anti-dsDNA', 'DAT_Coombs']" } }, "required": ["jak2_mutated", "megakaryocyte_clustering", "megakaryocyte_atypia"] } }, { "name": "analyze_iron_overload_axis", "description": "Models transfusional vs. hepcidin-mediated reticuloendothelial iron trapping based on ferritin, TSAT, transfusion volume, and inflammatory cytokine parameters.", "inputSchema": { "type": "object", "properties": { "serum_ferritin_ng_ml": {"type": "number"}, "transferrin_saturation_pct": {"type": "number"}, "cumulative_prbc_units": {"type": "integer"}, "bone_marrow_hemosiderin_grade": { "type": "string", "enum": ["0", "1+", "2+", "3+", "4+"] }, "concurrent_autoimmune_flare": {"type": "boolean"} }, "required": ["serum_ferritin_ng_ml", "transferrin_saturation_pct"] } } ] } ``` --- ## 8. Primary Literature References & Citations 1. **Paquette RL, Meshkinpour A, Rosen PJ.** Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. *Medicine (Baltimore)*. 1994 May;73(3):145–52. [PMID: 8190038]. 2. **Bass RD, Pullarkat V, Feinstein DI, Brynes RK.** Pathology of autoimmune myelofibrosis: a study of 8 cases. *Am J Clin Pathol*. 2001;116:611. 3. **Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK.** Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. *Am J Hematol*. 2003 Jan;72(1):8–12. [PMID: 12508261]. 4. **Vergara-Lluri ME, Piatek CI, Pullarkat V, Siddiqi IN, O’Connell C, Feinstein DI, Brynes RK.** Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. *Hum Pathol*. 2014 Nov;45(11):2183–91. [PMID: 25242220]. 5. **Piatek CI, Vergara-Lluri ME, Pullarkat V, Siddiqi IN, O’Connell C, Brynes RK, Feinstein DI.** Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome. *Acta Haematol*. 2017;138(3):129–37. [PMID: 28848123]. 6. **Mertz P, Chalayer E, Martin T, Arnaud L, Amoura Z, et al.** Clinical spectrum and therapeutic management of auto-immune myelofibrosis: a nation-wide study of 30 cases. *Haematologica*. 2021 Feb;106(2):617–20. [PMID: 32616538]. 7. **Gangat N, Reichard K, Orazi A, Tefferi A.** Autoimmune myelofibrosis: A Mayo Clinic series of 22 patients. *Br J Haematol*. 2024 Sep;205(3):838–44. [PMID: 38769748]. 8. **Nemeth E, Ganz T.** Hepcidin and iron in health and disease. *Annu Rev Med*. 2023;74:261–77. [PMID: 36252277]. 9. **Ganz T.** Systemic iron homeostasis. *Physiol Rev*. 2013 Oct;93(4):1721–41. [PMID: 24137020]. 10. **Angelucci E, et al. (TELESTO Investigators).** Deferasirox versus placebo in iron-overloaded patients with lower-risk myelodysplastic syndromes: the TELESTO randomized clinical trial. *Ann Intern Med*. 2020;172(8):513–22. 11. **Guglielmelli P, et al.** Impact of mutation profile on the course and outcomes of triple-negative myelofibrosis. *Blood*. 2014;124(21):1839. 12. **Tefferi A, et al.** Targeted next-generation sequencing in primary myelofibrosis: a prospective analysis of 500 patients. *Leukemia*. 2018;32(4):898–906. 13. **Vainchenker W, Kralovics R.** Genetic basis and molecular mechanisms of myeloproliferative neoplasms. *Blood*. 2017;129(6):667–79. 14. **Gangat N, Tefferi A.** Myelofibrosis: Biology and management. *Br J Haematol*. 2023;200(3):284–98. 15. **Pullarkat V.** Autoimmune myelofibrosis: clinical and pathological aspects. *Curr Hematol Rep*. 2005;4(3):225–9.